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The unprecedented emergence of multiple avian influenza virus (AIV) 
subtypes with a broad host range poses a major challenge in the design of vaccination 
strategies that are effective against multiple subtypes of influenza. The present study 
focused on the protective effects of a modified AIV as a backbone for epidemic and 
pandemic influenza. In addition, the ability of this backbone to induce heterosubtypic 
immunity (Het-I) was also analyzed. Het-I is the ability of one influenza subtype to 
protect against a different influenza subtype. Previously, a live attenuated AIV with 
the internal backbone of A/guinea fowl/Hong Kong/WF10/99 (H9N2) (WF10), called 
WF10att, protected chickens against a lethal influenza challenge. To characterize the 
WF10att backbone as a master donor strain and determine its ability to induce Het-I, 
we evaluated its protective efficacy in mice and ferrets.  Vaccinated mice were 
protected against homologous challenge with A/WSN/1933 (H1N1) (WSN), mouse-
adapted A/California/04/2009 (pH1N1) and A/Vietnam/1203/2004 (H5N1) (HPAI 
  
H5N1) viruses, and ferrets survived homologous challenge with HPAI H5N1. 
H7N2att vaccinated mice were protected against both H1N1 and HPAI H5N1 
challenge; however, Het-I was observed in H9N2att vaccinated ferrets challenged 
with HPAI H5N1.  
We found that both B and T cells are involved in the Het-I induced by our 
WF10att backbone. Cross-reactive non-neutralizing antibodies to viral proteins were 
detected. JhD-/- mice, which lack mature B-lymphocytes, were vaccinated with the 
recombinant vaccines and challenged with HPAI H5N1. None of the vaccinated mice 
survived challenge further suggesting a role for Het-I. In addition, cells isolated from 
the lungs of H7N2att vaccinated mice had cross-reactive antibody-secreting cells 
targeted to HPAI H5N1. Together, these results suggest a role for B cells in Het-I. 
Although B cells are important, T cells may also play a role in Het-I. Both IFN-γ and 
Granzyme B secreting cells were detected in lung and spleen cells isolated from 
H7N2att vaccinated mice and stimulated with HPAI H5N1 suggesting a role for T 
cells in Het-I. The ability of our WF10att backbone to induce Het-I depends on the 
surface glycoproteins expressed and the challenge virus subtype. In addition, 
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Chapter 1: Introduction 
1.1 General Introduction 
Influenza viruses belong to the Orthomyxoviridae. Three types of influenza 
viruses, Type A, B and C, exist and are differentiated from each other by two viral 
proteins, nucleoprotein (NP) and matrix 1 (M1). There are key differences as well, 
including the length of RNA generated, the number of segments each virus contains, 
and the amount of variation within the virus segments.  Both type A and B viruses 
have 8 RNA segments while type C has 7 RNA segments (Palese and Young 1982). 
Influenza A viruses have a broad host range, infecting birds, pigs, horses, sea 
mammals, dogs, civets and humans. Influenza B viruses infect only humans and seals 
(Osterhaus, Rimmelzwaan et al. 2000); influenza C viruses infect only humans and 
pigs (Guo, Jin et al. 1983). Influenza A viruses undergo more genetic variation than 
both influenza B and C viruses resulting in pandemics and seasonal epidemics while 
influenza B causes seasonal epidemics, and influenza C viruses are inconsequential to 
humans or pigs (Palese and Young 1982).  
Influenza A viruses are further subdivided into subtypes; 16 hemagglutinin (HA) 
subtypes and 9 neuraminidase (NA) subtypes have been described so far (Webster, 
Bean et al. 1992).  Only two subtypes currently circulate in humans, H1N1 and 
H3N2. Previously, the H2N2 subtype circulated in humans from 1957 to 1968 
(Nabel, Wei et al. 2011). Wild aquatic birds are considered the natural reservoir for 
influenza A viruses and contain all the HA and NA subtypes (Webster, Bean et al. 




birds. The virus is transmitted among avian species through the fecal-oral route 
(Webster, Bean et al. 1992). Birds secrete high concentrations of virus (up to 108.7 
50% egg infectious dose (EID50) per gram) into the environment (Webster, Yakhno et 
al. 1978). Virus has been isolated from unconcentrated lake water as well as fecal 
material indicating that waterfowl efficiently transmit influenza A viruses by fecal 
contamination of the water supply (Webster, Bean et al. 1992). This transmission not 
only occurs between birds, but the virus can be transmitted to other species as well. In 
addition as a result of migration patterns, numerous young birds gather at specific 
areas each year and are exposed to the many viruses present, creating a high 
incidence of influenza infection among birds (Webster, Bean et al. 1992). The genetic 
diversity within this reservoir is sufficient to cause a pandemic because the genetic 
variability of influenza viruses is generated by 1) point mutations that occur during 
replication by the viral polymerase which has no proofreading capability (antigenic 
drift) and 2) genetic reassortment between two viruses infecting the same cell 
(antigenic shift) (Webster, Bean et al. 1992). 
Disease signs caused by influenza A viruses vary in the avian species and depend 
on the age and species of the bird, the strain of the virus, the environment and the 
presence of bacterial infection. Some influenza strains are asymptomatic in birds, 
possibly due to the adaptation of these viruses to birds for centuries and are 
considered low pathogenic avian influenza viruses (LPAI). Other strains cause severe 
disease signs involving infection of the respiratory tract and central nervous system 
resulting in death within one week or less. These viruses are called highly pathogenic 




H5N1 viruses are now endemic in many parts of the world including Asia, Europe, 
the Middle East, and some African countries. HPAI H5N1 has pandemic potential 
because it has infected additional species including leopards, tigers, cats, stone 
martens, and humans (Sandrock and Kelly 2007). 
In May 1997, a previously healthy three-year-old boy had a febrile respiratory 
tract illness. HPAI H5N1 virus was isolated from the boy on day 10 of the illness and 
the boy died from complications on day 16 (Subbarao, Klimov et al. 1998).   Similar 
to the 1918 pandemic virus, all genes from this HPAI H5N1 virus was of avian origin 
(Claas, Osterhaus et al. 1998; Horimoto and Kawaoka 2001). In November and 
December of 1997, there were 17 additional cases of laboratory-confirmed H5N1 in 
Hong Kong residents, making a total of 18 confirmed HPAI H5N1 cases, which 
resulted in 6 deaths in patients ranging from 1 to 60 years old. The clinical signs of 
the HPAI H5N1 infection were indistinguishable from H1N1 or H3N2 infections, 
however the rate of complications was higher (Subbarao and Katz 2000). During the 
human outbreaks of HPAI H5N1 in November and December of 1997, there were 
concomitant outbreaks of HPAI H5N1 in chickens in poultry markets and farms 
(Shortridge, Zhou et al. 1998). In 1999, 2001, 2002 and 2003, HPAI H5N1 outbreaks 
occurred in chickens in Hong Kong, and two human cases were reported in the 2003 
outbreak. In December of 2003, HPAI H5N1 spread to poultry in Korea and China 
(Suarez 2010). From 2003 to 2006, the poultry outbreak spread throughout the world 
and resulted in 256 cases of human HPAI H5N1 infection and 151 fatalities (WHO 
2011).  As of October 10, 2011, 15 countries have 566 confirmed human cases of 




Transmission of avian influenza viruses to humans is not restricted to the HPAI 
H5N1 viruses. In March 1999, H9N2 viruses were isolated from two children 
hospitalized in Hong Kong with mild respiratory disease. Both illnesses resolved 
without complication in 5-6 days (Peiris, Yuen et al. 1999). One patient was exposed 
to chickens in the weeks prior to her illness. H9N2 viruses were known to circulate 
amongst chickens and other avian species in live bird markets (Guan, Shortridge et al. 
1999); however mild signs were seen in those birds. Since 1999, H9N2 viruses have 
been isolated in humans infrequently in China (Guo, Li et al. 1999; Butt, Smith et al. 
2005). Recent serologic surveillance studies in both China and Iran have detected 
antibodies to H9N2 viruses in the sera of freshman entering a university in Guangxi, 
China (13.69%) (Chen, Ge et al. 2008), healthy poultry workers in Guangzhou, China 
(4.5%) (Wang, Fu et al. 2009), and the general population of Iran (2.5%) (Hadipour 
and Pazira 2011) suggesting that humans are exposed to H9N2 viruses frequently 
resulting in seroconversion. In contrast to H5N1 viruses, the illnesses associated with 
H9N2 viruses in both humans and birds are mild; however similar to H5N1 viruses, 
H9N2 viruses are endemic to poultry in parts of Asia and the Middle East. Therefore, 
both viruses remain a pandemic threat.  
At the end of February 2003, outbreaks of H7N7 avian influenza occurred in 
commercial poultry farms in the Netherlands. The virus spread to 255 farms and 
resulted in the culling of an estimated 30 million chickens—28% of the total 
Netherlands chicken population (Koopmans, Wilbrink et al. 2004). The H7N7 virus 
that transmitted from poultry to humans was related to a LPAI detected in ducks 




internal genes were of avian origin (Fouchier, Schneeberger et al. 2004). There have 
been previous reports of H7 associated conjunctivitis in humans caused by laboratory 
or occupational exposure (Webster, Hinshaw et al. 1981; Kurtz, Manvell et al. 1996; 
Alexander and Brown 2000). During the Netherlands outbreak in 2003, 86 people 
involved in the culling of infected chickens and 3 of their family members, with no 
contact with chickens, were infected with the H7N7 virus resulting in 1 fatality. 
Among these people, 78 had conjunctivitis, 5 had conjunctivitis and respiratory 
symptoms, and 2 had respiratory symptoms. The one individual who died was a 
veterinarian who visited many of the infected farms; he developed acute respiratory 
distress syndrome and fatal pneumonia (Belser, Bridges et al. 2009).   
Most epidemiological studies have determined that the human cases of avian 
influenza came from contact with domesticated poultry. Contact includes 
consumption of undercooked or raw poultry products, handling of sick or dead birds 
without protection, or food processing at bird cleaning sites. These data suggest that 
interspecies transmission from birds to mammals occurs and tends to be self-limiting; 
the newly introduced viruses do not seem to be maintained through human-to-human 
transmission (Webster, Bean et al. 1992). However, limited human-to-human 
transmission has been reported previously with health care workers and family 
members (Katz, Lim et al. 1999; Buxton Bridges, Katz et al. 2000; Liem and Lim 
2005; Ungchusak, Auewarakul et al. 2005). In the case of HPAI H5N1, since it has a 
high case-fatality associated with infection and the ability to mutate and adapt to 
other hosts, it remains a public health concern. However, any avian influenza has the 




There are two FDA approved human influenza vaccines, inactivated and live 
attenuated.  Both are trivalent vaccines containing two type A influenza virus 
subtypes, H1N1 and H3N2, and one type B influenza virus. Inactivated vaccines are 
approved for use in commercial poultry. Although they are approved for use, 
inactivated vaccines are rarely used in developed countries. Usually, extraordinary 
circumstances are required before vaccines can be used. If inactivated vaccines are 
used in the field for commercial poultry, an oil emulsion vaccine can be formulated 
and used based on the field isolate circulating in the flocks. The vaccine is injected 
into birds subcutaneously or intramuscularly. The ability to mass administer poultry 
vaccines is extremely important and offers significant savings to poultry producers 
and would increase usage of the vaccines. Another important component of vaccines 
for poultry is the differentiation of infected from vaccinated animals, or DIVA 
strategy. The most common method is using a different neuraminidase gene than the 
circulating influenza virus is carrying. Not being able to determine if animals are 
vaccinated or infected could result in trade restrictions being imposed by other 
countries (Kapczynski and Swayne 2009). 
 Although there are approved vaccines available for humans and other animal 
species, improvements can be made to the current vaccines. A big downside of 
seasonal vaccines is the long production time required.  Vaccines are produced in 
embryonated chicken eggs; one egg produces one to three doses of inactivated 
vaccine. Therefore, it usually takes 6 months for the vaccine to be produced and ready 
for use. A way to solve this dilemma is to use animal cells to produce vaccines. This 




strains will be circulating during the influenza season.  This in turn would result in 
closer matched strains in the vaccine that are more reflective of circulating viruses in 
nature. The biggest problem facing current vaccines is their inability to protect 
against antigenically different viruses, causing the need to produce new vaccines 
annually that contain a closer matched virus. This is what happened with the 2009 
novel H1N1 pandemic that occurred in the spring of 2009.  The H1N1 strain in the 
seasonal vaccine was unable to protect against the pandemic H1N1 virus; therefore, a 
monovalent pandemic vaccine was produced and available by December of 2009. 
More research is needed to develop more effective seasonal and pandemic vaccines 
that provide long-lasting immunity and broad protection against strains that differ 
antigenically from the vaccine viruses (Fiore, Bridges et al. 2009). 
1.2 Research Objectives 
 The main goal of this dissertation was to determine a possible mechanism for 
the induction of heterosubtypic immunity (Het-I) induced by a live attenuated vaccine 
backbone. Current influenza vaccines for humans and other species are unable to 
protect against circulating influenza viruses that are antigenically different from the 
vaccine reference strains. Therefore, understanding the immunological components of 
a vaccine required to induce protection against antigenically distinct viruses will 
result in improved vaccines. To address this, we first sought to develop a live 
attenuated vaccine for poultry as one is currently not available. Thus, we decided to 
use A/guinea fowl/Hong Kong/WF10/1999 (H9N2) (WF10) virus as our backbone 
and transferred the cold-adapted (ca), temperature sensitive (ts) and attenuated (att) 




was protective in poultry against LPAI and HPAI H5N1 viruses (Song, Nieto et al. 
2007).  Subsequently, we focused on the ability of our avian influenza backbone, 
WF10att, to protect mammals, both mice and ferrets, from homotypic and 
heterosubtypic challenge, the induction of Het-I, and the mechanism for Het-I 
induction.  
 
The research objectives were: 
 
I. Determine if the WF10att backbone can be used as a master donor strain for 
live attenuated vaccines for epidemic and pandemic influenza in mammals, 
using the mouse and ferret models. 
 
II. Determine if the WF10att backbone expressing H7N2 or H9N2 surface 
glycoproteins can induce Het-I in the mouse and ferret models. 
 
III. Elucidate the possible mechanism(s) of Het-I induced by WF10att backbone in 
the mouse model. 
1.3 Major Findings 
I. WF10att expressing H1N1, H7N2, or H9N2 surface glycoproteins was 
protective in Balb/c mice against H1N1 challenge suggesting that WF10att 
can be used as a master donor. 
 
II. Only Balb/c mice immunized with WF10att expressing ΔH5N1 or H7N2 




against HPAI H5N1 challenge, indicating that depending on the surface 
proteins present Het-I can be induced by our backbone. 
 
III. Ferrets immunized with WF10att expressing ΔH5N1 or H9N2 surface 
glycoproteins had increased survival against HPAI H5N1 challenge than 
ferrets immunized with WF10att expressing H7N2 surface glycoprotein, 
suggesting Het-I is species specific and depends on the subtypes used for 
challenge. 
 
IV. Cross neutralizing antibodies against the heterosubtypic virus were not 
detected suggesting that other mechanisms are involved in Het-I. 
 
V. Antibody secreting cells directed to βPL-inactivated ΔH5N1 virus were 
secreted from cells isolated from H7N2att immunized Balb/c mice and 
stimulated in vitro with βPL-inactivated ΔH5N1 virus further suggesting a 
role for antibodies in Het-I. 
 
VI. IFN-γ was secreted from cells isolated from H7N2att immunized Balb/c mice 
and stimulated in vitro with βPL-inactivated ΔH5N1 virus suggesting a role 





VII. Granzyme B was secreted from spleen cells isolated from H7N2att 
immunized Balb/c mice and stimulated in vitro with Concanavalin A 





Chapter 2: Influenza: Life cycle, Pandemics, Vaccination 
and Immunity 
2.1 Influenza Virus 
2.1.1 Discovery of Influenza 
 It is thought that influenza has existed for centuries. Hippocrates described a 
typical influenza epidemic in Greece in 412 BC (Klenk 2008). Influenza was 
originally named fowl plague by Perroncito in 1878 to describe a disease affecting 
poultry in Northern Italy (Perroncito 1878). Later, fowl plague spread from Italy to 
Austria and Germany, and later to Belgium and France (reviewed in (Lupiani and 
Reddy 2009)). Clinical signs displayed were distinct from fowl cholera, a bacterial 
disease, and infected fowl had hemorrhagic lesions in many organs including the 
brain (Klenk 2008). In 1901, Centanni characterized fowl plague as a virus (FPV) 
because the agent was able to pass through bacterial filters and because the agent 
could be passaged “indefinitely” in chickens (Centanni 1901). FPV was specific for 
different bird species; however, mammals were not susceptible to the disease. The 
virus was propagated in embryonated eggs, and Landsteiner and Berlinger determined 
the virus needed living cells in order to replicate (reviewed in (Klenk 2008)). By the 
mid 1900s, FPV infected most areas including most of Europe, Russia, North 
America, South America, the Middle East, Africa, and Asia (reviewed in (Lupiani 
and Reddy 2009)). In 1954, Schafer demonstrated FPV and influenza A virus were 




2008)). Shope and Lewis isolated the first influenza virus during 1930, which was a 
swine influenza virus (Shope 1931). Three years later, the first virus was isolated 
from a human in 1933 (Smith 1933). 
2.1.2 Virion Morphology and Genome Structure 
The influenza A virion derives its lipid membrane from the plasma membrane 
of the host cell.  The HA, neuraminidase (NA), and the matrix 2 (M2) proteins project 
from the virion (Fig 1); there are 4 HA molecules to every 1 NA molecule on the 
surface. The overall composition of the virion is 1% RNA, 5-8% carbohydrate, 20% 
lipid, and about 70% protein (Fields Virology 2007).  The influenza virion is 
pleomorphic, but the spherical particles have a diameter of about 100 nanometers 
(nm) (Fields Virology 2007). Filamentous particles have been observed in fresh 
clinical isolates (Chu, Dawson et al. 1949) and have a length of 300 nm.  The matrix 
(M) gene seems to be a major determinant of this difference in morphology although 
the HA and NA proteins my play a role as well (Varghese, Colman et al. 1997). 
Inside the virion is the matrix 1 (M1) protein that forms the scaffold just below the 
lipid membrane. Bound to the scaffolding are eight segments of single stranded 
negative sense RNA (Fields Virology 2007).  Each RNA segment is coated with NP 
proteins and is associated with the components of the viral RNA polymerase—
Polymerase basic protein 1 (PB1), Polymerase basic protein 2 (PB2), and the 












Figure 1. Influenza A virion. The virus contains a lipid bilayer derived from the host 
plasma membrane.  Two surface glycoproteins, HA and NA, are the major antigenic 
determinants of the virus.  The HA protein is responsible for binding sialic acid 
receptors on the host cell surface.  Human influenza viruses bind preferentially sialic 
acids in an alpha 2,6 conformation (α2-6 gal), while those from avian species bind 
mostly to sialic acids in an alpha 2,3 conformation (α2-3 gal).  The virion also 
contains several copies of an ion channel proton pump (M2) on the surface. Eight 
vRNA segments, each one of them associated to three polymerase subunits (PB2, 
PB1, and PA), and several copies of the nucleoprotein (NP) are located inside the 
virion protected by a protein mesh provided by the matrix protein (M1).  In addition, 
the virus carries few copies of the virus encoded Nuclear Export Protein (NEP/NS2).  
In infected cells, the virus expresses NS1, which interferes with the antiviral state 
mounted by the cell.  Some influenza strains express PB1-F2, a ~80 aa peptide, 
derived from the second open reading frame of segment 2 that encodes PB1.  PB1-F2 
has been shown to modulate apoptosis in certain cell types infected with influenza. 
 





The eight RNA segments encode up to 11 proteins.  Each viral segment 
contains noncoding regions at both the 5’ and 3’ ends, portions of these ends are 
conserved among all segments and a segment specific noncoding region follows this 
sequence. Segments 1, 2, and 3 encode components of the viral polymerase PB2, 
PB1, and PA, respectively (Fields Virology 2007).  Depending on the virus, segment 
2 can also encode PB1-F2, which is involved in the induction of host-cell apoptosis 
(Lamb and Takeda 2001). Segment 4 encodes the HA protein important for viral 
attachment to host receptors on the cell surface (Connor, Kawaoka et al. 1994). NP is 
encoded by segment 5 and interacts with the viral RNA to form ribonucleoproteins 
(RNPs) (Baudin, Bach et al. 1994). Segment 6 encodes the NA protein, which is 
responsible for cleaving sialic acids (SAs) resulting in the release of newly formed 
virions from the host cell (Fields Virology 2007). Segment 7 encodes the M1 and M2 
proteins.  As mentioned previously, the M1 protein provides rigidity to the virion 
(Fields Virology 2007), and the M2 is a ion channel that allows protons to enter and 
acidify the inside of the virion resulting in fusion of the virion with the endosome and 
release of RNPs into the cytosol (reviewed in (Lamb, Holsinger et al. 1994)). The 
final segment 8 encodes the nonstructural protein-1 (NS1) and nonstructural protein-2 
(NS2) or nuclear export protein (NEP). NS1 is a multifunctional protein and plays a 
role in antagonizing the host’s immune response to influenza.  NS2 is responsible for 
exporting RNPs out of the nucleus and into the cytoplasm (Fields Virology 2007). 
2.1.3 Orthomyxovirus Family 
The Orthomyxoviridae is defined as viruses with negative sense, single 




mucus and separate them from the other negative stranded viruses, Paramyxovirdae 
(Fields Virology 2007). There are five genera in this family including Influenza A, B, 
C, Thogotovirus, and Isavirus (Table 1).  The Thogotovirus genus consists of two 
viruses, Dhori virus and Thogoto virus, both isolated from ticks.  The Isavirus genus 
consists of infectious salmon anemia virus (Fields Virology 2007).  
Influenza A, B, and C viruses can be distinguished by antigenic differences in 
the nucleoprotein (NP) and matrix (M) proteins (Palese and Young 1982). In addition, 
type A viruses infect a wide variety of species including both bird species and 
mammals. Type B viruses infect only humans, and type C viruses are able to infect 
humans and pigs. There are also morphologic differences between the three types of 
influenza viruses (Palese and Young 1982; Fields Virology 2007). Influenza A 
viruses have increased sequence variability within the HA and NA proteins when 
compared to influenza B viruses. Influenza C viruses do not contain HA and NA 
proteins. In place of those proteins, influenza C viruses carry a hemagglutinin 
esterase-fusion (HEF) protein.  Each of the genera expresses very similar proteins; 
however, they have different functions. Also, influenza A and B viruses have 8 RNA 
segments while influenza C has 7 RNA segments. This section will focus on 







 Table 1. Orthomyxovirdae 
Genus Genome Hosts 
Influenza virus A 8 RNA segments Birds, Humans, Pigs, Horses 
Influenza virus B 8 RNA segments Humans, Seals 
Influenza virus C 7 RNA segments Humans, Pigs 
Isavirus 8 RNA segments Salmon 





2.1.4 Virus Entry 
Influenza A viruses recognize sialic acids (SA) expressed on host cell surface 
proteins. Therefore, these SA receptors limit the viral cell and tissue tropism, 
interspecies transmission, and adaptation of influenza viruses to new hosts. Host cell 
surface receptors contain 5-N-acetylneuraminic acid (Neu5Ac), which is the 
prototypical SA.  SAs are negatively charged 9 carbon sugars at the ends of 
oligosaccharide chains of glycoproteins and glycolipids. These Neu5Ac can be linked 
to the third or sixth carbon of the sugar galactose creating a α2,3 SA or α2,6 SA. 
Different strains of influenza viruses recognize different linkages of SAs.  Generally, 
human influenza viruses recognize the α2,6 SAs and avian viruses recognize the α2,3 
SAs (Matrosovich, Stech et al. 2009). 
The globular head of the influenza HA contains the SA binding site, called the 
receptor-binding site (RBS); however, the RBS has a weak affinity for the SA.  It 
takes many interactions between the amino acid residues of the HA and host cell 
receptor to gain tight binding. Many factors besides HA affinity for the receptor affect 
the ability of influenza viruses to bind their receptors including the abundance and 
availability of receptors on the host cell surface and the structure of oligosaccharide 
beneath the SA on the receptors.  As a result, the receptor-binding properties of 
influenza viruses can be drastically changed by mutations to the amino acid residues 
resulting in altered glycosylation or electric charge inside the SA-binding pocket of 
the HA, on the pocket rim, or distant mutations (Matrosovich, Stech et al. 2009).  
Once attached to its host receptor, influenza virus is taken up by endocytosis 




nonclatherin, noncaveolae pathways, or 4) through macropinocytosis.  Clathrin-
mediated endocytosis is the most discussed mechanism of influenza virus entry; 
however, other forms of internalization have been observed (Fields Virology 2007). 
Previous research has observed that influenza is still infectious when clathrin-
mediated endocytosis is blocked, indicating that influenza can use an alternative 
pathway to enter the cell (Lakadamyali, Rust et al. 2004). The internalized virus is 
within an endosome where the pH becomes acidic as the endosome matures.  Earlier 
in infection, the HA0 precursor is cleaved into HA1 and HA2. At low pH, the viral 
membrane fuses with the endosomal membrane when the HA2 undergoes a 
conformational change and the fusion peptide is exposed. Multiple HA2 fusion 
peptides and the transmembrane domains of the HA2 molecules open up a pore that 
releases the viral ribonucleoprotein (vRNP) into the cytoplasm. The timing and 
location of the release of the vRNPs, whether it is the early or late endosome, depends 
on the HA molecules involved (Stegmann, Morselt et al. 1987; Fields Virology 
2007).  
Weak bases such as ammonium chloride and chloroquine or ionophores are 
able to block the uncoating of influenza viruses.  In addition, the M2 protein ion 
channel is also very important for uncoating because the protein is responsible for 
allowing the entrance of protons (H+) into the virion, which creates a low pH 
environment. A low pH disrupts protein-protein interactions therefore freeing vRNPs 
from M1 and allowing their release from the virion (Lamb, Holsinger et al. 1994). 
Antivirals, amantadine and rimantadine, block the M2 channel preventing viral 




Once the vRNPs are released into the cytoplasm, they must enter the nucleus 
where viral replication takes place. The vRNP consists of the viral RNA (vRNA) 
coated completely in nucleocapsid protein (NP) and is in a helical hairpin shape 
(Fields Virology 2007). 
2.1.5 Viral Replication 
 All eight RNAs of influenza virus never exist as naked RNA; instead they are 
associated with the NP protein and the 3 subunits of the viral polymerase. The viral 
polymerase consists of the PB2, PB1, and PA subunits.  PB2 is responsible for 
binding the cap of host pre-mRNA, which is necessary to prime viral mRNA 
synthesis. PB1 is the catalytic subunit that elongates the RNA, (Fields Virology 2007) 
and PA has endonuclease activity (Dias, Bouvier et al. 2009). In addition to 
endonuclease activity, mutational studies show a role for PA in cRNA synthesis 
(Bucher, Hemmes et al. 2004), cap snatching (Bui, Myers et al. 2002), cap binding 
and vRNA promoter recognition (Bui, Whittaker et al. 1996). Binding of the 
polymerase subunits to the 5’ and 3’ ends of the vRNA creates a panhandle structure 
(Hsu, Parvin et al. 1987). NP protein is essential for virus RNA transcription and 
replication as naked vRNA is not an efficient template. NP protein coats the vRNA 
and covers the sugar phosphate backbone while exposing the RNA bases (Fields 
Virology 2007). 
Due to their large size, vRNPs are unable to diffuse into the nucleus from the 
cytoplasm of an infected cell. Therefore, all vRNAs contain a nuclear localization 
signal (NLS) to allow their association with the nuclear import machinery (Smith, 




Palese et al. 1997; Weber, Kochs et al. 1998). The NLS(s) are on NP and are 
sufficient and necessary for the import of the vRNPs (O'Neill, Jaskunas et al. 1995; 
Cros, Garcia-Sastre et al. 2005). Once the vRNPs reach the nucleus, the vRNAs are 
transcribed into mRNA. Viral mRNA synthesis is dependent on host RNA 
polymerase II activity. Prior to binding the vRNA, the polymerase complex is 
enzymatically inactive. Transcription occurs when the 5’ end of the vRNA binds the 
PB1 subunit of the viral polymerase, which causes an allosteric change resulting in 
the activation of PB2 cap binding activity (Fields Virology 2007). PB2 binds the cap 
of the host pre-mRNAs; this binding causes a change in the polymerase structure that 
increases the affinity for the 3’ end of the vRNA.  PB1 binds the 3’ end of the vRNA, 
which stabilizes the polymerase complex and causes an allosteric change that 
activates the endonuclease activity of PA.  PA cleaves 10-13 nucleotides downstream 
of the host cap creating a primer for viral transcription (Dias, Bouvier et al. 2009).  
Nucleotides are added to the primer by the PB1 subunit. This continues until a stretch 
of approximately 5-7 uridine nucleotides are encountered by the viral polymerase, 
which causes the polymerase to stutter and add a string of adenosine nucleotides 
creating the polyadenylation at the end of the viral mRNA molecule (Fields Virology 
2007).  
Although vRNA is the template for both mRNA and cRNA, cRNA does not 
contain a cap or poly A tail, is not primer initiated, and is full-length positive strand 
versions of the vRNA. As a result, there are two steps needed to replicate vRNAs: 1) 
synthesis of template RNAs, which is cRNA and 2) copying the template into vRNAs 




there are ideas of how the full-length cRNA is created. Soluble NP protein seems to 
play an important role in the antitermination of cRNA.  NP binds the 5’ end of the 
nascent RNA chain potentially covering up the stretch of 5-7 uridine nucleotides used 
to create the poly A tail for the viral mRNA (Fields Virology 2007).  Covering these 
uridine residues prevents backward slipping by the viral polymerase; therefore, 
polymerase continues adding nucleotides until a full-length cRNA is created. 
Following replication, M1 protein and NEP/NS2 help export vRNPs from the nucleus 
to the cytoplasm (Fields Virology 2007).  
2.1.6 Viral Assembly 
Assembly and budding of influenza viruses occurs from the apical membrane 
of polarized cells, which results in a restricted tissue tropism of these viruses. HA, 
NA, and M2 proteins localize to the apical surface and are associated with lipid rafts 
present on the cell surface. Lipid rafts are nonionic detergent resistant lipid 
microdomains within (reviewed in (Rossman and Lamb 2011)) the plasma membrane 
that are rich in sphinoglipids and cholesterol (Ono and Freed 2005). They concentrate 
proteins within defined regions of the plasma membrane thus serving as functional 
domains (Lingwood and Simons). The M1 protein is the most abundant virion protein 
and is believed to make contact with both vRNPs and the cytoplasmic tails of the 
glycoproteins. The M1 protein is absolutely required for assembly, however very 
little is known about how the other viral components reach the assembly site and are 
packaged into the virion. It is hypothesized that M1 binds the vRNPs and by 
associating with the glycoproteins during their passage through the exocytic pathway 




assembly site where HA, NA, and M2 localize and brings along the vRNP-NEP/NS2 
complex (Fields Virology 2007). An alternative model is the M1-vRNP complex uses 
the cytoskeleton to reach the assembly site because NP and M1 have been shown to 
interact with the cytoskeleton components (Avalos, Yu et al. 1997). 
 The mechanism by which exactly 8 RNA segments are packaged into the 
virion is not fully understood; however, there are 2 models. The first is the random 
incorporation model that hypothesizes that there are common structural features 
present on all the vRNPs that ensures their random incorporation into the virion 
(Fields Virology 2007). This model is supported by the fact that there exist virions 
containing more than 8 vRNPs, assuring the presence of a full complement of eight 
vRNPs in a significant percentage of virus particles (Enami, Sharma et al. 1991; 
Bancroft and Parslow 2002).  The second model is the selective incorporation model 
that states each vRNP acts independently resulting in each segment being packaged 
individually because each segment has packaging signals. Coding regions of the NA 
(Fujii, Goto et al. 2003), HA (Watanabe, Watanabe et al. 2003), NS (Fujii, Fujii et al. 
2005), PB2, PB1, and PA (Liang, Hong et al. 2005; Muramoto, Takada et al. 2006) 
segments have all been demonstrated to increase the ability of a reporter sequence to 
be incorporated within assembling virions. Segment specific packaging is thought to 
occur through RNA-RNA or protein-RNA interactions which allow diverging 
sequences of influenza to be packaged into the virion (Fields Virology 2007). 
2.1.7 Viral Budding 
 Lipid rafts facilitate the budding of the viruses so influenza viruses 




al. 2000). HA and NA associate with lipid raft domains. The 27 residue 
transmembrane (TM) domain of HA contains 1 palmitoylated cysteine residue and 2 
palmitoylated cysteine residues are located in the cytoplasmic tail, which mediate 
lipid raft association. This association is important for viral replication (Chen, Takeda 
et al. 2005). According to previous research involving virus like particles (VLPs), HA 
was able to alter membrane curvature in the absence of other viral proteins. In the 
absence of HA and NA, M2 could also alter membrane curvature but to a lesser 
extent. Although HA is able to initiate budding, it seems as though the other viral 
proteins are required to complete the budding process. Deletion and mutational 
studies have shown deletion and mutation of the HA does not alter the number of 
virions budding, suggesting that other proteins are able to initiate budding such as 
NA. Mutational studies with the M2 protein indicate an essential role for M2 in the 
budding process. Lack of M2 prevents release of virions, therefore M2 is involved in 
the completion of budding but not initiation (reviewed in (Rossman and Lamb 2011)). 
 The size and shape of the influenza virus particle is determined by the extent 
the membrane is extruded before pinching off. Usually the particle will be either 
spherical or filamentous, and the shape is dependent on the M protein (Smirnov Yu, 
Kuznetsova et al. 1991; Roberts, Lamb et al. 1998; Bourmakina and Garcia-Sastre 
2003; Elleman and Barclay 2004). After the virion has separated from the cell 
membrane during the budding process, the NA protein must actively release the 
virion. The HA protein binds SAs containing receptors on the cell surface keeping the 




the glycoproteins freeing the virion and preventing aggregation of the viruses on the 
cell surface (Fields Virology 2007). 
2.1.8 History of Pandemics 
 Influenza epidemics are common annual events that are unpredictable in time 
and severity.  They result from antigenic drift, which is the accumulation of point 
mutations in the hemagglutinin (HA) gene causing a change in antigenicity. However, 
pandemics result when two conditions occur: 1) an outbreak spreads throughout the 
world, a high percentage of individuals are infected, and there is an increase in 
mortality and 2) a new influenza subtype emerges that was not previously circulating 
in the human population, which is called antigenic shift. Many agree the first 
pandemic of influenza occurred in 1580 although there were previous reports of 
possible earlier pandemics (Potter 2001). It has been speculated that the first 
influenza pandemic occurred in 1173-74; (Hirsch 1883; Potter 2001) however, most 
believe this was just an outbreak. There are several reports from both the 14th and 15th 
centuries, however there is not enough information recorded to determine whether a 
pandemic occurred (Potter 2001). The first established pandemic in 1580 originated 
in Asia during the summer and spread to Africa and Europe (Pyle 1986). All of 
Europe was infected within 6 months, and the virus eventually spread to America 
(Pyle 1986; Beveridge 1991). During this pandemic, illness rates were high and 
thousands died (Beveridge 1991). 
Although there are records indicating that influenza pandemics occurred 
during the 17th century, data from the 18th century is more definitive that an influenza 




AD in Russia during the spring (Hirsch 1883; Finkler 1899; Pyle 1986; Patterson 
1987).  It quickly spread to Europe and affected the whole continent within 6 months, 
(Pyle 1986) and within 3 years the entire known world was infected with this virus 
resulting in high death rates. There were distinct waves of infection with the first 
waves being less severe than the latter (Brown 1932; Beveridge 1977; Patterson 
1987). The next pandemic occurred over 40 years later in 1781-82 (Finkler 1899; 
Pyle 1986).  This pandemic started in China during autumn and spread to Russia and 
then encompassed all of Europe within an 8-month period (Pyle 1984).  The rate of 
infection was high among young adults (Thompson 1890). More pandemics were 
recorded during the 19th century, and the first started during the winter in China in 
1830-33 and had similar severity to the famous 1918 Spanish flu (Beveridge 1977; 
Pyle 1986; Patterson 1987). This pandemic spread south to the Philippines, India, and 
Indonesia, and eventually moved to Russia and then Europe. The pandemic spread to 
North America in 1831-32 and then reoccurred in Europe at the same time and 
reoccurred in Europe again in 1832-33 (Pyle 1984). There was a high infection rate of 
20-25% of the population; however, the mortality rate was relatively low (Patterson 
1987).  
 Influenza pandemics were recoded four times during the 20th century (Jordan 
1927; Burnet 1942; Pyle 1986; Patterson 1987). The greatest pandemic occurred in 
1918-20 and was caused by an H1N1 virus with unknown origin. The first outbreaks 
occurred simultaneously in March 1918 in North America in Detroit, South Carolina, 
and San Quentin Prison in California (Crosby 1989). Infection spread outward and 




from North America to Europe and later Russia by the transport of soldiers and 
supplies.  By May 1918, North Africa was infected, and then the virus moved to other 
areas in Africa before spreading to China, New Zealand and the Philippines in June 
1918. In each country, infection spread quickly for a few weeks then sharply 
declined. The events of March-July 1918 were not exceptional and the numbers of 
deaths recorded were comparable to previous pandemics. August 1918 saw a second 
wave of infection in Sierra Leone that was more virulent than the previous outbreaks 
resulting in a 10-fold increase in deaths. A second wave hit Europe and spread 
quickly throughout the continent and this virus was more virulent as well.  This more 
virulent virus spread all over the world and resulted in millions of deaths mainly in 
adults aged 20-40 years (Potter 2001). It is estimated that 50% of the world’s 
population was infected, 25% suffered a clinical infection and the total mortality was 
between 40-50 million (Crosby 1976).  
The next pandemic occurred in 1957-58 when a reassortment between an 
avian and human influenza created the H2N2 Asian influenza virus, which replaced 
the previous circulating H1N1 virus (Tscherne and Garcia-Sastre 2011). This H2N2 
virus, which harbored the PB1 segment from an avian virus (Potter 2001), originated 
in China during February and spread rapidly to Singapore, Taiwan, and Japan. Later it 
spread to the Southern hemisphere during the winter then spread to the Northern 
hemisphere during its winter. The pandemic was mainly transmitted among sea travel 
and within 6 months, the pandemic had spanned the globe. Deaths were estimated to 
be 1 in every 4000 individuals and primarily affected the elderly and the very young 




reassorted to generate an H3N2 virus that replaced the then circulating H2N2 virus 
(Tscherne and Garcia-Sastre 2011). In July 1968, the H3N2 virus was first isolated in 
Hong Kong, and by August, spread rapidly to Singapore, Thailand, Taiwan, and 
Vietnam.  By September, Australia, Iran, India, and the US were all infected.  The 
virus affected all age groups. In general, symptoms were mild and no increases in 
deaths were reported; however, some areas were hit harder than others. For example, 
the U.S. experienced an increase in deaths equaling mortality rates that were seen 
during the 1957-58 pandemic; this was unique to the 1968 pandemic (Vernick 2010).  
The first pandemic of the 21st century originated in Mexico during March and 
April of 2009 and was caused by a H1N1 swine-origin influenza virus (WHO 2009). 
During the late 1990s, triple-reassortant H3N2 and H1N2 viruses evolved when North 
American avian and human H3N2 and H1N2 viruses exchanged genetic material 
(Dunham, Dugan et al. 2009; Garten, Davis et al. 2009). A swine triple reassortant 
virus then reassorted with a Eurasian avian-like swine virus to create the swine origin 
pandemic virus of 2009 (Tscherne and Garcia-Sastre 2011). The PB2 and PA genes 
from the pandemic virus are from an avian virus, PB1 is from a human seasonal 
H3N2 virus, the HA, nucleoprotein (NP), and nonstructural (NS) genes are from the 
classical swine virus (Dunham, Dugan et al. 2009; Garten, Davis et al. 2009). NA and 
M are from the European avian-like H1N1 lineage (Dunham, Dugan et al. 2009; 
Garten, Davis et al. 2009). In the spring, several areas in Mexico reported large 
numbers of patients displaying influenza-like symptoms, and by June 2009, 74 
countries had detected the virus and the WHO declared a pandemic (Fraser, Donnelly 




H1N1 virus. Infection with the pandemic H1N1 virus is indistinguishable from 
seasonal influenza except for the increase in the number of patients reporting 
gastrointestinal symptoms. In contrast to seasonal influenza, there was an increase in 
infection in the younger population as opposed to the elderly (Tscherne and Garcia-
Sastre 2011). Since emerging in spring of 2009, the pandemic H1N1 virus is the 
predominant H1N1 subtype circulating in humans, replacing the seasonal H1N1 virus 
(WHO 2009). 
2.2 Influenza A Virus Ecology 
2.2.1 Influenza A Viruses in Birds 
The ecology of influenza A viruses is extremely complicated involving 
various viral genes and many different species. Wild aquatic birds, especially 
migrating waterfowl, are considered the natural reservoir of influenza A viruses and 
contain all the 16 HA and 9 NA subtypes (Hinshaw, Webster et al. 1980). The clinical 
signs and disease observed in wild aquatic birds depend on the age of the bird, strain 
of the virus, environment, and presence of bacteria in the bird (Alexander and Brown 
2000). Avian influenza viruses infect a limited number of cell types usually located in 
the gastrointestinal tract of birds resulting from the ingestion of the virus. In birds, the 
virus is transmitted by the fecal-oral route because birds excrete high amounts of 
virus in feces contaminating the water. Virus-contaminated water serves as a vector 
for the spread of the virus to other birds and other species. The migrating nature of 
birds allows for the dissemination of influenza viruses to different geographical areas, 
and the interaction of different bird species carrying all influenza subtypes along 




Some influenza infections are asymptomatic in the bird reservoir; on occasion 
when the species barrier is crossed, these viruses can cause severe disease in birds, 
especially domesticated birds, humans, pigs, and some other species. Although all 16 
HA and 9 NA subtypes are found in wild aquatic birds, not all can replicate in 
domesticated poultry without prior adaptation.  In gallinaceous poultry, influenza A 
viruses are designated low pathogenic avian influenza (LPAI) or highly pathogenic 
avian influenza (HPAI). LPAI cause mild to no disease in birds while HPAI have 
polybasic cleavage sites in the HA gene that facilitates systemic replication of these 
viruses. Systemic replication results in viruses that can kill birds in one week or less. 
Since 2002, HPAI H5N1 viruses that replicate more efficiently in the trachea and not 
the intestines of ducks have emerged. This change in replication can change the route 
of transmission of influenza between birds, switching from a fecal-oral route to 
inhalation, which is the mode of transmission of human influenza (Boyce, Sandrock 
et al. 2009). 
Domestic poultry may be an important intermediate host of influenza virus. It 
has been established that aquatic birds contain a vast array of influenza variability; 
however, poultry may come in contact with these birds.  On several occasions in the 
past, HPAI H5N1 and H7N7 influenza outbreaks in domestic poultry were 
transmitted to humans resulting in deaths (Subbarao, Klimov et al. 1998; Guan, 
Shortridge et al. 1999; Guo, Li et al. 1999; Koopmans, Wilbrink et al. 2004; Butt, 
Smith et al. 2005). In addition, LPAI H9N2 was also transmitted to humans (Guo, Li 
et al. 1999; Peiris, Yuen et al. 1999; Butt, Smith et al. 2005), and both the 1997 HPAI 




phylogenic lineage. Fortunately, human-to-human transmission has been limited and 
usually, humans have been dead end hosts after the virus has jumped the species 
barrier (Webster, Bean et al. 1992). However, limited human-to-human transmission 
has been reported previously in health care workers and family members (Katz, Lim 
et al. 1999; Buxton Bridges, Katz et al. 2000; Liem and Lim 2005; Ungchusak, 
Auewarakul et al. 2005). 
Wild aquatic birds are considered the natural reservoir for influenza A viruses; 
however, viruses from the natural reservoir must mutate before they can cross the 
species barrier to infect humans because these viruses replicate poorly in humans 
(Webster, Yakhno et al. 1978; Hinshaw, Bean et al. 1980; Hinshaw, Webster et al. 
1980). Because land-based poultry are farmed around the world and have been 
involved in the spread of avian influenza to humans resulting in deaths, it is important 
to understand the role of land-based poultry as potential intermediates of influenza 
reassortant viruses. Sorrell et al examined the role of quail in the generation of 
influenza viruses with increased host range and found an H2N2 virus adapted in quail 
mutated resulting in the transmission and replication of the virus in both chickens and 
quail, which was a increase in host range (Sorrell and Perez 2007).  In addition, the 
virus did not lose its ability to infect and transmit in mallard ducks (Sorrell and Perez 
2007). These results suggest that land-based birds may act as intermediate hosts in the 
spread of influenza A viruses.  
H2N2 viruses are not the only subtype found to increase its host range when 
adapted in land-based poultry. Hossain et al adapted an H9N2 virus in quail and 




2008). These adapted viruses were readily able to infect mice providing further 
evidence that land-based poultry can act as intermediated hosts (Hossain, Hickman et 
al. 2008). H9N2 viruses isolated from 1988 to 2003 were tested for their ability to 
replicate in the ferret model. The viruses were able to replicate, partially transmit to 
direct contacts, and were unable to transmit to respiratory droplet contacts (Wan, 
Sorrell et al. 2008). H9N2 avian-human reassortant virus containing the internal 
genes from a human H3N2 virus and the surface genes from an H9N2 virus was 
characterized in the ferret model.  There was an increase in replication in multiple 
respiratory tissues of the ferret with the H9N2 avian-human reassortant virus when 
compared to wholly H9N2 virus and the reassortant virus efficiently transmitted to 
direct contacts; however, still no respiratory droplet transmission was observed (Wan, 
Sorrell et al. 2008). In addition, the H9N2 avian-human reassortant virus induced 
clinical signs similar to the parental wild type H3N2 virus suggesting the 
establishment and prevalence of H9N2 viruses in poultry pose a significant threat for 
humans (Wan, Sorrell et al. 2008). 
Since H9N2 viruses are endemic in countries throughout the world and have 
transmitted to both humans and pigs, the question arises whether an avian-human 
H9N2 reassortment can gain the ability to transmit by respiratory droplet in 
mammals. An H9N2 avian-human reassortant virus containing the HA and NA from 
an H9N2 virus and the six internal genes from an H3N2 virus was adapted in ferrets 
resulting in a virus that transmitted by respiratory droplet. Minimal mutations were 
found in the adapted virus and a reassortant virus expressing the HA and NA genes 




phenotype, suggesting currently circulating avian H9N2 viruses require little 
adaptation in mammals to create viruses that can transmit by aerosol (Sorrell, Wan et 
al. 2009). Therefore, aerosolized respiratory transmission is not exclusive to current 
human H1, H2, and H3 influenza subtypes (Sorrell, Wan et al. 2009).  
2.2.2 Influenza A Viruses in other species 
 For an estimated 70 years, classical swine influenza (cH1N1) circulated as the 
predominant subtype in pigs in the U.S. until 1998 (Ma, Lager et al. 2009). Influenza 
was first observed in swine in 1918 and 1919 during the Spanish flu pandemic, and 
cH1N1 virus is antigenically similar to the 1918 pandemic H1N1 virus. Clinical signs 
of influenza in swine include nasal discharge, coughing, fever, labored breathing, and 
conjunctivitis (Shope 1931; Shope 1958). In 1998, a swine influenza-like outbreak 
occurred in North Carolina and spread to pig farms in Minnesota, Iowa, and Texas. 
An H3N2 influenza A virus was identified as the causative agent. The virus from 
North Carolina was a double reassortant containing genes from cH1N1 virus (PB2, 
PA, NP, M, NS) and genes from a recent human virus (PB1, HA, NA). However, the 
virus isolated from Minnesota, Iowa, and Texas was an A/H3N2 triple reassortant 
virus containing the genes from cH1N1 (NP, M, NS), genes from a human virus 
(PB1, HA, NA), and genes from an avian virus (PA, PB2) (Zhou, Senne et al. 1999). 
By the end of 1999, viruses antigenically similar to the triple reassortant were 
widespread in the U.S. swine population (Webby, Swenson et al. 2000).  
 Since then, H3N2 and cH1N1 viruses have coevolved, resulting in the 
identification of H3N2 (Webby, Swenson et al. 2000; Richt, Lager et al. 2003; 




2002), reassortant H1N1 (rH1N1) (Webby, Rossow et al. 2004), and H3N1 
(Lekcharoensuk, Lager et al. 2006; Ma, Gramer et al. 2006) genotypes in pigs. H3N2, 
rH1N1, and H1N2 viruses are endemic in swine in the U.S. and Canada and continue 
to co-circulate. Recently, human H1-like viruses, which are distinct from cH1N1 
viruses, have been introduced into swine in Canada (Karasin, Carman et al. 2006). 
However, all swine viruses maintain the original triple reassortant internal genes 
(PB2, PB1, PA, M, NP, NS) known as the triple reassortant internal gene (TRIG) 
cassette. 
 Pigs are considered a “mixing vessel” because they can be infected with both 
avian and human influenza viruses due to having α2,3 and α2,6 sialic acids in their 
respiratory tract (Ito, Couceiro et al. 1998). This allows for possible reassortment 
resulting in the generation of novel influenza viruses that may cause a pandemic. 
There are three parts to the mixing vessel hypothesis: 1) swine are susceptible to 
human and avian viruses, 2) reassortment of human and avian viruses occur within 
the swine, and 3) swine transmit influenza A to humans. Although swine are thought 
to be an intermediate host between birds and humans, the documentation of birds, 
especially domesticated birds transmitting influenza to humans, has complicated the 
interspecies transmission scenario. 
  Equine influenza (EI) is a very important respiratory disease of horses 
and was first isolated from horses in 1956 (Sovinova, Tumova et al. 1958). The 
disease is characterized by pyrexia, coughing, nasal discharge, loss of appetite, 
tracheobronchitis, and muscle soreness (Webster, Bean et al. 1992; van Maanen and 




rate remains low unless viral infection is accompanied by bacterial infection, which is 
common, or horses are continuously worked.  
 The spread of EI in horses in controlled by vaccines, which were introduced in 
the 1960s in Europe and North America. Most vaccines are adjuvant-inactivated 
viruses or subunit vaccine and contain H7N7 (Equine 1 viruses) and H3N8 (Equine 2 
viruses) subtypes; however, H7N7 viruses have not been isolated from horses since 
1977 and are considered extinct (Webster 1993). EI viruses are more genetically 
stable than human and avian influenza viruses, but antigenic drift does occur and 
impacts vaccine efficiency. Several changes have occurred to the H3N8 viruses since 
the 1960s. H3N8 viruses were evolving as a single lineage (Kawaoka, Bean et al. 
1989), until they diverged into a Eurasian and American lineage based on 
geographical distribution (Daly, Lai et al. 1996). Viruses from the American lineage 
predominated and spread internationally resulting in three sublineages—Argentina, 
Kentucky, and Florida (Lai, Chambers et al. 2001).  
  In the U.S., approximately 20% of harbor seals died of severe 
respiratory infection from 1979 to 1980. H7N7 virus (A/Seal/Massachusetts/1/1980) 
was found at high concentrations in the lungs and brain of these dead seals (Geraci, St 
Aubin et al. 1982). The virus was related to avian influenza viruses; however when 
tested experimentally, the virus replicated efficiently in mammalian animal models, 
including ferrets, cats, and pigs. In contrast, the virus replicated poorly in avian 
species and resulted in no clinical signs of disease and was not detected in the feces. 
In addition, humans were infected with the virus and only conjunctivitis occurred; 




The mode of transmission to the seals is unknown—either virus was transmitted from 
birds or influenza viruses have been circulating undetected in seals. It is hypothesized 
that birds were the source of the virus because there is no serological evidence of 
influenza in the surviving animals, and there is no further evidence of influenza in 
seals since 1980s. In 1983, an H4N5 virus was isolated from dead seals on the New 
England coast and, as before, the virus was related to avian influenza; these two cases 
raised concern that some human or mammalian influenza viruses are derived from 
avian viruses. 
2.3 Animal Models Used to Study Influenza Virus 
2.3.1 Overview 
Efforts remain to completely understand the pathogenesis of influenza, 
develop new vaccines to prevent influenza, and develop new treatments for influenza. 
As a result, it is imperative to have laboratory animal models that reflect human 
influenza virus infection (Barnard 2009). The ultimate goal of any animal model is to 
mimic disease outcomes in humans; therefore, an animal model must shed light on 
human disease.  There are several animals models used to study influenza infection. 
The model used will depend on the focus of the study. The most common animal 
models include mice and ferrets; however, there are many more that are used 
including the guinea pig, Syrian hamster, chinchilla, hedgehog, many avian species, 
pigs, nonhuman primates, and the rat (Maher and DeStefano 2004; Barnard 2009). 





2.3.2 Mice as a model for influenza A virus 
The mouse is commonly used as a model for influenza infection to study viral 
pathogenesis, and development of vaccines and antiviral agents due to its size and 
low cost.  It allows researchers to use large numbers of animals, which are easy to 
house. In addition, there are numerous reagents to study the immune response to 
infection as well as knockout mice lacking immune components. Mice do not display 
all of the clinical symptoms observed in humans infected with influenza including 
fever, coughing, sneezing, increase in rectal temperature, and nasal discharge 
(Barnard 2009). However, mice do display some clinical signs similar to humans 
infected with influenza that allow researchers to assess the severity of the disease. 
These include reduced blood oxygen saturation levels, which are a measure of lung 
function (Barnard 2009). These levels are dramatically lower in mice approaching 
death. In addition, weight loss, cytokine levels, viral lung titers, and serum proteins 
can be measured to monitor the severity of the disease (Sidwell 2004; Barnard 2009). 
However, there are downsides to using mice, including the fact they are not a natural 
host of influenza (Maher and DeStefano 2004); most human influenza viruses do not 
cause disease in mice, and therefore, most strains need to be adapted to mice prior to 
experimentation, except for some highly pathogenic avian influenza (HPAI) H5N1 
strains (Barnard 2009). Also, mice do not transmit the virus by respiratory droplet to 
neighboring animals, and most laboratory mouse strains lack the myxovirus 
resistance (Mx) gene, which plays a role in the innate host defense against influenza 




2.3.3 Ferrets as a model for influenza A virus 
Ferrets are considered the ideal model for influenza vaccine efficiency 
assessments because they are naturally susceptible to human influenza viruses both A 
and B subtypes, and they have similar clinical signs, pathogenesis, and immunity 
displayed by humans infected with influenza. The ferret has been used in influenza 
research since 1933. As a result, many of the contemporary concepts of immunity to 
influenza virus have been established.  The signs and clinical course of influenza 
infection in ferrets is similar to that observed in humans. In both ferrets and humans 
the clinical signs displayed depend on the age of the host, strain of the virus, 
environmental conditions, and the degree of secondary bacterial infection. Infection is 
restricted to the upper respiratory tract and both display clinical signs including 
sneezing, nasal discharge, malaise, anoxia, watery eyes, and fever. Also, the duration 
of the disease is acute in both species, lasting 3-5 days in cases where there are no 
complications. Infected ferrets are able to transmit the disease to other ferrets or 
humans through respiratory droplets, and the pathogenesis of influenza A virus in 
ferrets is similar to the pathogenesis in humans (Maher and DeStefano 2004). Ferrets 
are outbred animals unlike other animal models used to study influenza virus, which 
creates variability in immune responses. This variability may mimic humans’ immune 
responses to disease. Also, ferrets are the only small animal model that develop fever 
to naturally occurring influenza A viruses similar to humans (Maher and DeStefano 
2004). Although there are many positives to using ferrets as a model of influenza, 
there are many downsides including the fact that ferrets are expensive and are less 




there is no inbred or specific-pathogen free (SPF) animals available, and there are 
limited or no reagents to study the immune response. 
2.4 Influenza Vaccines and Antivirals 
2.4.1 Overview 
Current influenza vaccines are trivalent and contain representative influenza A 
(H3N2), influenza A (H1N1), and influenza B viruses anticipated to circulate that 
year using viral surveillance data (Fiore, Bridges et al. 2009). Each year the World 
Health Organization (WHO) and the US Public Heath Service (PHS) recommend the 
reference strains that should be part of the vaccine. Because the HA and NA undergo 
antigenic drift, the vaccines must be updated annually. Effectiveness of influenza 
vaccines is associated with age of the vaccinee, immune competence of the vaccinee, 
and the antigenic relatedness of the vaccine strains to circulating strains in nature. 
When vaccine strains are well matched, they are 70-90% effective in randomized, 
placebo-controlled trials conducted among children and healthy adults. However, this 
is not true among the elderly and immunocompromised individuals where 
effectiveness is much lower (Fiore, Bridges et al. 2009); vaccine efficiency drops to 
40-60% in the elderly (Govaert, Sprenger et al. 1994). There are currently two types 
of vaccines approved for use in humans, inactivated vaccines and live attenuated 
cold-adapted vaccines (Fiore, Bridges et al. 2009). Vaccine viruses are created using 
the internal genes from A/Puerto Rico/8/34 (H1N1) (PR8) for inactivated vaccines 
and the cold-adapted A/Ann Arbor/6/60 (H2N2) for live attenuated vaccines, and the 
HA and NA from the three circulating wildtype viruses that make up the vaccine for 




vaccines in eggs for mass production. B/Ann Arbor/1/66 is the master donor strain for 
B viruses (Kilbourne, Schulman et al. 1971; Fiore, Bridges et al. 2009). 
 Although there are vaccines available for influenza virus, improved vaccines 
are still needed. Vaccines need to be more efficacious in certain populations including 
young children, the elderly, and the immunocompromised. Children have the highest 
influenza infection rates, as high as 30-40% in an epidemic, and most need to be 
hospitalized (Cox, Brokstad et al. 2004). Influenza infection in adults >65 years old 
or the immunocompromised can result in severe illness, complications from infection, 
and even death (Cox, Brokstad et al. 2004). In addition to diminished efficacy in 
certain populations, there are other improvements needed for current influenza 
vaccines. The substrate used is a major disadvantage.  The egg supply needed to grow 
the vaccine has to be prepared well in advance because large quantities of eggs are 
needed to grow large amounts of vaccine.  One egg produces 1-3 doses of vaccine. 
Eggs are also susceptible to microbial contamination, which can delay production. 
There is a possibility that some human influenza viruses may not grow well in eggs, 
which would lead to further delays. Individuals may have egg allergies and are unable 
to be vaccinated with egg-derived vaccines (Fields Virology 2007; Fiore, Bridges et 
al. 2009). There have been studies that suggest that eggs may change the antigenic 
composition of the HA protein and introduce mutations that promote egg growth, 
which may lead to decreased immunogenicity of the vaccines (Katz, Naeve et al. 
1987; Williams and Robertson 1993). Changing to tissue culture-based vaccine 




currently available vaccines is their inability to induce broad protection against 
multiple strains of influenza virus. 
2.4.2 Inactivated Vaccines 
The first commercial vaccine was approved for use in humans in the United 
States in 1945 (Fiore, Bridges et al. 2009). High growth reassortants are created using 
the internal gene segments from the master donor strain PR8 and the HA and NA 
gene from the circulating H1N1 and H3N2 influenza A viruses. The influenza seed 
viruses are replicated in eggs and then the vaccine virus is harvested from the 
allantoic fluid, purified, concentrated by zonal centrifugation or column 
chromatography, and then inactivated using either formalin (Fiore, Bridges et al. 
2009). Purification techniques have greatly reduced the number of local and systemic 
reactions; however, the vaccine still contains trace amounts of endotoxin, egg-derived 
protein, free formaldehyde, and most have thimerosal preservative (Fiore, Bridges et 
al. 2009). Although these contaminants may be present, they do not appear to 
contribute to the reactogenicity or toxicity of the vaccine for humans. The 
monovalent vaccines containing the H1N1, H3N2, and B influenza are combined to 
form the seasonal trivalent vaccines. There are two types of inactivated vaccines—
subvirion/split and whole virus vaccines (Fiore, Bridges et al. 2009).  The subvirion 
or split inactivated vaccines have been the predominant vaccines produced since the 
1970s and are prepared using a detergent that solubilizes the viral lipid envelope 
followed by chemical inactivation of residual virus. Whole inactivated vaccines are 




Inactivated influenza vaccines are intramuscularly injected and contain 15µg 
of HA for each vaccine strain for individuals greater than or equal to three years old 
and 7.5µg of HA for each strain for individuals 6-35 months old (Fiore, Bridges et al. 
2009).  The Advisory Committee on Immunization Practices (ACIP) recommends the 
standard dose of HA used in the vaccine (CDC 2011).  There is no standard quantity 
of NA in the vaccine because it is labile during the process of purification and storage 
(Fiore, Bridges et al. 2009). For children younger than nine years of age who have not 
previously been vaccinated, two doses, a priming dose followed by a booster dose 
four or more weeks after the first dose, are needed to induce a protective antibody 
response.  A booster dose is recommended due to younger children’s lack of exposure 
to prior influenza infection (Fiore, Bridges et al. 2009). The preparation of inactivated 
vaccines for the highly pathogenic H5N1 virus posed problems because the virus 
killed the embryo before enough virus was present to harvest. Creating reassortants 
with the master donor strain PR8 and removing the cleavage site from the H5 
molecule solved this problem. In addition, due to the poor immunogenicity of the H5 
protein, the standard dose of inactivated H5N1 is 90µg of HA per vaccine and 
multiple doses are necessary for protection (Enserink 2005). 
Inactivated vaccines induce antibodies to the two major surface proteins HA 
and NA; however, HA is the main immunogen in inactivated vaccines (Fiore, Bridges 
et al. 2009). Antibodies against HA are the key determinant in protection from 
infection against antigenically similar viruses, and antibodies directed toward NA are 
important for reducing disease (Fiore, Bridges et al. 2009). Due to the relative rapid 




previously, vaccines are usually 70-90% efficacious with the high value 
corresponding to protection against homologous virus and the low value 
corresponding to protection against viruses that have undergone antigenic drift (Fiore, 
Bridges et al. 2009). Resistance to circulating influenza viruses correlates with the 
level of hemagglutination inhibition (HAI) antibodies induced to the infecting strain 
(Fields Virology 2007). A titer of 1:32 or 1:40 is the benchmark for protection; 
however, these values are not absolute (Fiore, Bridges et al. 2009). In situations 
where the efficacy was low, the surface antigen of the epidemic virus differed from 
the vaccine virus or the vaccine was of low potency and did not stimulate high 
enough levels of antibodies to the epidemic virus. Inactivated vaccines have 
continued to be used for years due to their safety and efficacy (Fields Virology 2007). 
Inactivated vaccines for humans are based on epidemiologic, molecular, and 
antigenic data; however in poultry, state government and agricultural authorities 
determine the use of vaccines based on risk and economical considerations 
(Kapczynski and Swayne 2009). In the case of poultry, there are three types of 
vaccines approved for use including inactivated whole avian influenza vaccines, 
recombinant fowl poxvirus vector with avian H5 insert, and recombinant Newcastle 
disease virus with avian H5 HA gene insert (Swayne 2009). Poultry influenza 
vaccines should be used in conjunction with biosecurity, culling, diagnostics, and 
surveillance to be effective. The use of vaccines in poultry varies by country. In most 
developed countries vaccines are not used unless extraordinary circumstances occur 
(Kapczynski and Swayne 2009; Swayne 2009). In contrast, Asia, the Middle East, 




of field-inactivated vaccines are oil emulsion inactivated whole avian influenza 
vaccines that are injected subcutaneously or intramuscularly. Each vaccine is custom 
made against the specific HA subtype circulating amongst the birds in the field 
(Kapczynski and Swayne 2009). Usually two doses are necessary for protection and 
subsequent boosting is usually needed in long-lived birds.  The ability to mass 
administer poultry vaccines is extremely important and offers significant cost savings 
to poultry producers. Also, it would increase field usage as individual administration 
can be time-consuming (Kapczynski and Swayne 2009). 
2.4.3 Live Attenuated Vaccines 
Local immunity is thought to play a major role in resistance to respiratory 
pathogens. Immunization with live attenuated vaccines seems to be the most efficient 
method of stimulating such immunity. Infection of the respiratory tract stimulates 
both systemic and local immunity and also induces cell-mediated immunity (Fiore, 
Bridges et al. 2009). In order to develop effective live vaccines, vaccine 
manufacturers need to keep in mind that influenza viruses undergo significant 
antigenic variation. Therefore, it is not feasible to attenuate each new circulating 
variant of influenza that appears in nature by multiple passages within tissue culture.  
A strategy is needed in which attenuation can be achieved in a single step by 
transferring genes from an attenuated donor virus to each new epidemic or pandemic 
virus. The master donor strain A/Ann Arbor/6/60 (H2N2) was adapted to grow at a 
lower temperature by serially passaging the virus in primary chicken kidney cells 
while gradually lowering the temperature to 25°C until a mutant was recovered that 




are restricted for growth at 25°C. A virus that replicates efficiently at 25°C has 1) a 
temperature sensitive (ts) phenotype (restricted growth at 38-39°C), 2) a cold-adapted 
(ca) phenotype (efficient replication at 25°C), and 3) an attenuated (att) phenotype 
(lack of replication in the lungs of ferrets) (Maassab 1967). The amino acid mutations 
for these characteristics have been mapped within A/Ann Arbor/6/60 and are located 
in PB2 (N256S), PB1 (K391E, E581G, A661T), and in NP (D34G) (Jin, Lu et al. 
2003). The master donor strain used for influenza B viruses in the United States is 
B/Ann Arbor/1/66 (Fiore, Bridges et al. 2009).  
New live attenuated reassortant viruses are created using the six internal genes 
from the master donor strain plus the HA and NA genes from the epidemic virus 
circulating in nature. Live vaccines are grown in embryonated eggs similar to 
inactivated viruses and are trivalent containing H1N1, H3N2, and influenza B viruses.   
The allantoic fluid is harvested, pooled, clarified by filtration, and concentrated by 
ultracentrifugation. The vaccine consists of 106.5-7.5 fluorescent focus units (FFU) of 
each of the three strains (Fiore, Bridges et al. 2009). Live attenuated vaccines are 
administered intranasally and are recommended for use in children and non-pregnant 
individuals 2-49 years of age (Fiore, Bridges et al. 2009).  
Live attenuated viruses protect against experimental or natural infection with 
influenza A virus in adult and pediatric subjects that were exposed to influenza 
previously. In addition, live vaccines are immunogenic in seronegative individuals 
suggesting the vaccine would be protective in this population. A previous study 
observed that children aged 15-71 months, who were given 1 or 2 does of the trivalent 




influenza A/H3N2 and B (Belshe, Gruber et al. 2000). In the elderly, co-
administration of live vaccine and inactivated vaccine is more efficacious than 
inactivated vaccine administered alone (Tian, Buckler-White et al. 1985). Different 
vaccines and schedule of vaccination are necessary for different populations; as a 
result, the suggestions for yearly immunizations vary depending on the population. 
These suggestions include: 1) pediatric population older than 6 months should receive 
live vaccine because it is more immunogenic in this population, 2) previously primed 
children and adults <65 years old should receive live or inactivated vaccine because 
efficacies are comparable in these populations, and 3) the elderly (>65 years of age) 
should be co-administered live vaccine and inactivated vaccine because a 
combination is more efficacious in this population. Unlike inactivated vaccines, 
correlates of protection are less clear for live vaccines; therefore serum HAI antibody 
does not correlate with protective immunity (Clover, Crawford et al. 1991). 
In contrast to humans, live attenuated vaccines are not approved for use in 
commercial poultry because it is feared that the vaccine could reassort with wildtype 
viruses circulating with the flocks, especially H5 and H7 subtypes, creating a new 
virulent strain. LPAI of the H5 and H7 subtypes have demonstrated the ability to 
mutate (gain polybasic cleavage site in HA) into HPAI. Live attenuated vaccines also 
have the ability to cause economic losses due to respiratory disease caused by virus 
replication and could spread to surrounding farms (Kapczynski and Swayne 2009).  
Until live attenuated vaccines are able to overcome these obstacles, inactivated 





 Since influenza has a short incubation period, with a mean of 1.9 days, and has 
a range of symptoms from asymptomatic to acute primary viral pneumonia, 
surveillance and quarantine alone are not effective strategies to contain a pandemic. 
Therefore, antivirals and vaccines are required in order to curb the effects of a 
pandemic. Pandemic plans in countries around the world contemplate the stockpiling 
of sufficient doses of vaccine candidates and courses of approved antivirals, which 
could be deployed in the event of a pandemic. Since it is plausible that the antigenic 
make up of the stockpiled vaccine candidate does not fully match the pandemic strain 
and thus may not be fully protective, the access to effective antivirals is essential. 
There are several parameters that would determine which antivirals are used in the 
event of a pandemic such as efficacy of prophylaxis, treatment, ease of 
administration, tolerability, and safety. The best use of antivirals may be as 
prophylactic treatments in instances were individuals are most likely exposed to 
infection and where transmission is at its highest risk (Hayden 2001). There has to be 
enough antivirals stockpiled and a distribution strategy must be created before a 
pandemic occurs in order for antivirals to be effective (Longini, Halloran et al. 2004). 
Because there are several steps within the influenza virus life cycle, there are several 
different approaches and agents that can be used to reduce or eliminate virus 
propagation. These steps include viral entry, uncoating, replication, viral protein 
translation, viral budding, and the signal cascade events triggered during influenza 
infection.  




prophylaxis of influenza infection. These two classes consist of M2 inhibitors, 
amantadine (Symmetrel) and rimantadine (Flumadine); and neuraminidase inhibitors 
(NAIs), oseltamivir (Tamiflu) and zanamivir (Relenza). M2 inhibitors are anti-
influenza drugs that target the viral M2 protein and are only effective against type A 
influenza viruses. Amantadine was first approved by the Food and Drug 
Administration (FDA) in 1966 and was used prophylactically during the 1968 H3N2 
Hong Kong pandemic and 1977 H1N1 reappearance (Hayden 2001; Fields Virology 
2007). Rimantadine was not approved until 1993 (Fields Virology 2007). The M2 
protein is a unidirectional proton (H+) pump that promotes the acidification of the 
virus’s interior during entry by endocytosis and allows the release of the viral genome 
into the cytoplasm (Pinto, Holsinger et al. 1992). Unfortunately, the use of M2 
inhibitors leads to the emergence of resistant strains that remain fully infectious, 
which limits the use of these drugs (Jackson, Roberts et al. 2000; Hayden 2001; 
Bright, Medina et al. 2005; Bright, Shay et al. 2006; De Clercq 2006; Ong and 
Hayden 2007). The most common mutation found in these isolates is a substitution of 
a bulkier asparagine for serine at position 31 (N31S) (Ong and Hayden 2007), which 
prevents the binding of the drug while still maintaining the H+ activity. It has been 
observed that some H5N1 strains that emerged from Asia were resistant to M2 
inhibitors (Smith, Naipospos et al. 2006; Hurt, Selleck et al. 2007) leading to the 
speculation that they arose as a consequence of the improper use of these drugs to 
contain outbreaks in poultry. 
 NA’s main function is to cleave terminal SA residues on the receptors located 




in virus entry by cleaving off SA residues present in mucopolysaccharides, which 
would otherwise prevent the virus from binding to the cell surface SA receptors. 
NAIs bind the NA at the cleavage site preventing the processing of SAs and the 
release of viral particles (Varghese, Smith et al. 1998; De Clercq 2006). Currently the 
United States has approved two NAIs, zanamivir and oseltamivir, for the use in 
influenza prophylaxis and/or treatment (Hayden 2001). Oseltamivir is administered 
orally at a dose of 75mg twice a day, and it is available in tablet and liquid forms (De 
Clercq and Neyts 2007). Some animal studies suggest that the virulence of the disease 
may require an adjustment of the dose and length of time that the drug is administered 
(Yen, Monto et al. 2005). A change in the route of administration (intravenous) may 
be used for more ill patients (Hayden 2001). Zanamivir administration is performed 
using an inhaler device. There are advantages and disadvantages with the use of both 
drugs: Oseltamivir is easier to administer but results in systemic distribution and the 
possibility to cross the blood brain barrier as demonstrated in a rat model (Sweeny, 
Lynch et al. 2000). Zanamivir has localized distribution to the upper respiratory tract 
and thus is less effective against influenza infections that are characterized by heavy 
involvement of the lower respiratory tract as occurs with H5N1 viruses (Shinya, 
Ebina et al. 2006; De Clercq and Neyts 2007). Resistant strains to oseltamivir have 
been observed for human influenza viruses and H5N1 viruses, which could limit its 
use if the new pandemic virus is naturally resistant to it or if resistant strains are 
quickly selected for during the early stages of a pandemic. Due to the structure of 
zanamivir, it is thought that resistant strains are less likely to develop than with 




therefore, it is difficult to predict what could happen (Varghese, Smith et al. 1998). 
Resistant strains to NAIs have arisen through mutations within the globular head of 
the mushroom-shaped homotetrameric NA glycoprotein (Kiso, Mitamura et al. 2004). 
Mutations at positions 119 (E119V) in H3N2 viruses, 152 (R152K) and 198 (D198N) 
in influenza B viruses, 274 (H274Y) in H1N1 viruses, and 292 (R292K) in H3N2 and 
H4N2 viruses have been associated to resistance to NAIs (Kiso, Mitamura et al. 2004; 
De Clercq and Neyts 2007). A recent report compares sensitivity to NAIs of 55 
influenza A (H5N1) virus isolates. The majority of the isolates are sensitive to NAIs, 
but two strains are less sensitive due to two mutations (residues 116 and 117) within a 
highly conserved region (Singer, Nunn et al. 2007). Two other NAIs are at different 
stages of development; peramivir (Sidwell, Smee et al. 2001) and A315675 (Kati, 
Montgomery et al. 2002). Both have been shown to be effective against zanamivir- 
and oseltamivir-resistant strains (Mishin, Hayden et al. 2005). 
Although M2-inhibitors and NAIs decrease the symptoms associated with 
influenza infection, they have a limited time frame (48 h) from the onset of symptoms 
to be effective. Thus, due to the inherent shortcomings of the current available anti-
influenza drugs there is a need to explore other viable alternatives. 
2.5 Homotypic and Heterosubtypic Immunity 
2.5.1 Homotypic immunity 
Homotypic immunity is the ability of one strain of influenza virus to protect 
against another strain within the same subtype. Current seasonal influenza vaccines 
are able to induce homotypic immunity and protect against influenza strains that are 




against antigenically distinct strains. Homotypic immunity is primarily mediated by 
antibodies to the HA and NA. These antibodies neutralize and prevent infection by 
the challenge virus (Gerhard 2001). Homotypic immunity is usually effective for four 
or five years following the initial infection (Couch 2003). 
2.5.2 Heterosubtypic immunity 
Heterosubtypic immunity (Het-I) is the ability of one subtype of influenza to 
protect against multiple subtypes of influenza and has been studied for nearly fifty 
years (Schulman and Kilbourne 1965). It is hypothesized that Het-I is mediated by T 
cells that recognize epitopes in conserved influenza proteins, such as NP (Doherty, 
Topham et al. 1997; Subbarao, Murphy et al. 2006). Het-I immunity does not prevent 
infection, but does lower viral titers, accelerate viral clearance, and reduce morbidity 
and mortality. 
Vaccines that are able to induce Het-I are considered universal vaccines. 
Different strategies are used to develop universal vaccines. One strategy involves 
using conserved regions of the virus such as whole proteins or epitopes within viral 
proteins that can stimulate humoral or cell mediated immunity or both. 
Pharmaceutical companies are creating universal vaccines using a single conserved 
epitope. The influenza M2 protein forms a homotetramer and is a single-pass type III 
transmembrane protein within the viral lipid envelope responsible for allowing 
protons to enter the virion.  The decrease in pH within the virion results in the 
uncoating of the virion and release of the RNPs into the cytoplasm during viral entry 
(Schnell and Chou 2008). Great attention is being paid to the M2 ectodomain (M2e) 




M2 viral protein; M2e protein is conserved in both avian and human flu viruses and 
induces antibodies that inhibit broad spectrum influenza A subtypes in vitro and in 
vivo (Neirynck, Deroo et al. 1999; Stanekova and Vareckova 2010). However, these 
M2e antibodies are ineffective against type B strains because the ion channel is 
mediated by different proteins. Although antibodies are generated to the M2e peptide, 
M2e is less immunogenic than the HA and NA viral proteins (Feng, Zhang et al. 
2006); therefore, various approaches are being used to increase the immunogenicity 
of the M2e peptide (Neirynck, Deroo et al. 1999; Fiers, De Filette et al. 2004; De 
Filette, Ramne et al. 2006). 
Another viral target to develop a universal vaccine is the HA2 domain. HA2 is 
the C-terminal portion of the HA protein that forms a stem-like structure that anchors 
globular HA1domain to the viral membrane. Although the HA2 domain is less 
accessible than the HA1 domain, HA2-specific antibodies are induced during natural 
infection in humans (Styk, Russ et al. 1979) as well as mice (Kostolansky, Mucha et 
al. 2002). These HA2-specific antibodies have broad cross reactivity with many 
influenza subtypes (Vareckova, Cox et al. 2002; Gerhard, Mozdzanowska et al. 2006; 
Vareckova, Mucha et al. 2008; Stropkovska, Mucha et al. 2009; Steel, Lowen et al. 
2010); however, the antibodies do not neutralize influenza viruses and prevent 
binding of the virus (Becht, Huang et al. 1984; Russ, Polakova et al. 1987; Sanchez-
Fauquier, Villanueva et al. 1987). HA2-specific antibodies are able to decrease 
influenza replication levels using multiple mechanisms: 1) binding antibodies can 
inhibit the fusion of viral and endosomal membranes, (Edwards and Dimmock 2000; 




by low pH, (Okuno, Isegawa et al. 1993; Outlaw and Dimmock 1993; Imai, Sugimoto 
et al. 1998) or 3) by blocking the insertion of the fusion peptide into the endosomal 
membrane (Vareckova, Mucha et al. 2003; Vareckova, Wharton et al. 2003). In 
addition, removing the HA1 portion to create headless HA2 trimers that are more 
accessible to B cells than the native HA. Vaccination of mice with these headless 
HA2 elicited antibodies cross-reactive to several subtypes of influenza and protected 
mice from lethal challenge (Steel, Lowen et al. 2010). 
Other methods are being used to create universal influenza vaccines as well. 
Pharmaceutical companies have created vaccines using whole virus or proteins 
including the Gamma Flu vaccine, which is a whole inactivated virus (WIV) vaccine 
inactivated by gamma irradiation. Gamma irradiation destroys the genetic material in 
the virus (prevents replication); however, it leaves surface proteins intact. These 
intact proteins stimulate cytotoxic T cells and protects against multiple strains of 
influenza (Rudolph and Yedidia 2011). In pre-clinical trials, this strategy was shown 
to stimulate T cells (Furuya, Chan et al. 2010).  
Several pharmaceutical companies have products in pre-clinical and Phase I 
trials including in 2008 when VaxInnate reported positive results from a Phase I trail 
with their M2e-flagellin combined vaccine (VaxInnate 2008). Multi epitope vaccines, 
which are vaccines containing multiple conserved epitopes, are also being 
investigated for use as universal vaccines. The Dynavex vaccine containing an M2e 
epitope + NP + TLR9 immuno-stimulating sequence (ISS) provides protection 
against divergent strains by eliciting both T and B cell immunity (Dynavex 2010). A 




2010). Another company, Inovio, is in pre-clinical trials with its VGX™-3400 
vaccine, which is a prophylactic DNA vaccine that combines conserved regions of 
NA + M2e-NP + HA from H1, H2, H3, and H5 strains (Inovio 2010). Another 
approach used by Juvaris is to use synthetic tetrameric M2e-peptide antigens plus 
their JVRS-100 adjuvant. This vaccine is in pre-clinical trials and has been shown to 
induce significant Th1 biased antibody responses that are highly protective (Juvaris 
Biotherapeutics 2009). Other companies trying variations on the multiple epitope 
approach including SEEK, which designed a vaccine Flu-v that contains 6 highly 
conserved CTL epitopes and they are in Phase 1 trials (SEEK 2010). Immune 
Targeting Systems has a Phase I trial with FP01 which is comprised of 6 long (35 
amino acid) CD4+ and CD8+ conserved T cell epitopes administered as synthetic 
fluropeptides forming stable, immunogenic nanoparticles (Innovation 2010). 
Biondvax pharmaceuticals created a vaccine that stimulates both humoral and cell 
mediated immunity. The vaccine is in Phase II trials and consists of 9 conserved 
epitopes from HA, NP, M1 combined in a single recombinant protein expressed in E. 
coli (Ben-Yedidia and Arnon 2007; Biondvax 2010). The vaccine was tested in adults 
18-49 and older adults 55-75 found to be safe and successful; Also the vaccine 
protects against both influenza type A and B viruses (Ben-Yedidia and Arnon 2005; 
Biondvax 2010).  
Although there are several approaches underway to generate universal 
vaccines, the basic mechanism for Het-I is still unknown; according to the current 
literature, a variety of mechanisms are involved in Het-I.  Once these mechanisms are 




2.5.3 Role of T cells in heterosubtypic immunity 
Both natural infection and previous vaccination generate neutralizing 
antibodies that bind antigenically similar viruses and prevent them from entering cells 
of the respiratory tract. However, these antibodies are typically inadequate at 
protecting against serologically distinct strains (Cox, Brokstad et al. 2004; Thomas, 
Keating et al. 2006). Early reports demonstrated that mice and ferrets were protected 
from heterosubtypic influenza challenge in the absence of cross-reactive antibodies 
indicating that T cells may result in this protection (Tumpey, Renshaw et al. 2001; 
Kreijtz, Bodewes et al. 2009; Perrone, Ahmad et al. 2009). The surface glycoproteins 
undergo constant antigenic drift leading to antigenically distinct viruses. However, 
the internal genes are usually conserved between different influenza viruses. 
Therefore, it is commonly believed that T cells play an important role in 
heterosubtypic immunity (Het-I). T cells recognize viral peptides associated with 
major histocompatibility complex (MHC) I and II molecules. These T cells recognize 
highly conserved internal proteins, especially NP and M proteins. Pre-existing 
influenza-specific T cells do not prevent infection; however, they do help clear the 
virus and reduce pathology. It is believed that CD8+ cytotoxic T lymphocytes (CTLs) 
play the most significant role because they eliminate virus-infected cells by releasing 
perforin and/or inducing the Fas/Fas ligand apoptotic pathway (Furuya, Chan et al. ; 
Topham, Tripp et al. 1997; Trapani and Smyth 2002), and result in the release of 
cytokines, IFN-γ and TNF-α. In addition, CD4+ T cells are thought to play a role in 
Het-I; they may be involved in supporting and enhancing CD8+ T cell functions and 




Early studies demonstrated previous influenza infection resulted in cross-
reactive T cells, and showed these cross-reactive T cells were involved in Het-I. T 
cells isolated from the spleens of infected mice were transferred into naïve mice and 
decreased lung viral titers and increased survival upon heterosubtypic challenge (Yap 
and Ada 1978). This protection correlated with the cytotoxic activity of the 
transferred splenic T cells (Yap and Ada 1978). Later techniques were developed to 
culture CD8+ T cells in vitro, and it was shown that transferred CD8+ T cells 
protected mice from heterosubtypic challenge (Lin and Askonas 1981; Lukacher, 
Braciale et al. 1984).  
Most studies focusing on the mechanisms of Het-I have used live virus 
priming followed by heterosubtypic live virus challenge. Liang, et al performed 
depletion studies in mice primed with A/Puerto Rico/8/34 (H1N1) (PR8) and then 
challenged with A/Aichi/2/68 (H3N2) (X31). X31 is a reassortant virus containing the 
internal genes from PR8 and the surface glycoproteins from an H3N2 virus. These 
studies found that both CD8+ and CD4+ T cells were equally important in the 
induction of Het-I; however, the Het-I response was relatively short lived lasting 4-5 
months (Liang, Mozdzanowska et al. 1994). Benton, et al confirmed the role of CD8+ 
and CD4+ T cells in Het-I by priming Ig-/- mice with PR8 and challenging with H3N2 
(Benton, Misplon et al. 2001). Other studies have focused on the role that CD4+ T 
cells play in helping CD8+ T cells. Without CD4+ T cells, CD8+ T cells are impaired 
in their ability to clear the virus, clonally expand, and be recruited to the lungs from 




There have also been reports that different immunization strategies use T cells 
to induce Het-I. Earlier studies immunized outbred and inbred mice with a 
recombinant chimeric protein fusing the NS1 viral protein and HA2 subunit. These 
mice were challenged with a heterosubtypic virus and were protected from the 
challenge. Importantly, deleting both CD8+ and CD4+ T cells eliminated this 
protection (Kuwano, Scott et al. 1989; Mbawuike, Dillion et al. 1994). In addition to 
peptides, DNA immunizations have also induced Het-I (Ulmer, Donnelly et al. 1993; 
Epstein, Kong et al. 2005; Lo, Wu et al. 2008). Epstein, et al immunized mice i.n. or 
i.m. with recombinant Adenovirus (rAd) vectors expressing either viral NP protein or 
NP protein together with M protein. They found that mice were protected from 
heterosubtypic challenge with H1N1, H3N2, and HPAI H5N1, and this protection 
was also mediated by T cells (Price, Soboleski et al. ; Price, Soboleski et al. 2009).  
Few studies have focused on the ability of live attenuated vaccines to induce 
Het-I (Mak, Zhang et al. 1982; Tannock and Paul 1987). Powell, et al found depleting 
CD8+ T cells alone resulted in the death of Balb/c mice primed with a cold-adapted 
H3N2 virus and challenged with PR8 virus. In contrast, mice depleted of CD4+ T 
cells survived heterosubtypic challenge, indicating a role for CD8+ T cells in Het-I 
induced by a live attenuated virus (Powell, Strutt et al. 2007).  
 Although many reports suggest an important role for both CD8+ and CD4+ T 
cells in Het-I, T cells may not be absolutely required for Het-I as some studies 
suggest a role for other immune cells such as NK cells and γδ T cells; previous 
studies showed that CD8+ T cells may be dispensable for Het-I (Nguyen, van Ginkel 




and γδ T cells have overlapping functions. Elimination of one population may not 
completely impair Het-I because another cell type can compensate for the loss 
(Benton, Misplon et al. 2001). Therefore, more experiments are needed to tease apart 
the role of the different cellular components in Het-I. 
2.5.4 Role of B cells in heterosubtypic immunity 
  Most neutralizing antibody responses are directed toward the influenza HA 
and bind the exposed loop of HA1 that surrounds the receptor-binding site (RBS). 
These loops are variable between strains, and as a result, antibodies are usually strain 
specific. Influenza HAs cluster into two distinct groups on the basis of their primary 
sequence and major structural features (Air 1981; Nobusawa, Aoyama et al. 1991; 
Russell, Gamblin et al. 2004; Fouchier, Munster et al. 2005). Group 1 consists of 10 
of the 16 subtypes including H1, H2, H5, H6, H8, H9, H11, H12, H13, and H16. 
Group 2 consists of H3, H4, H7, H10, H14, and H15; due to these groupings, it is 
possible for cross-reactive antibodies to appear. Although a majority of antibodies are 
generated to the HA, antibodies specific for all the other viral proteins have been 
detected (LaMere, Lam et al. ; Zhang, Zharikova et al. 2006). Although the standard 
dogma is that T cells are important for Het-I because they can be directed toward 
conserved epitopes found in many influenza subtypes, some reports have 
demonstrated a role for B cells in Het-I (Nguyen, van Ginkel et al. 2001; Tumpey, 
Renshaw et al. 2001).  
As a mechanism for Het-I, some groups argue that B cells may be more important 
than CD8+ T cells (Nguyen, van Ginkel et al. 2001; Tumpey, Renshaw et al. 2001). 




which could be cross-reactive and bind the conserved regions of M2, HA or NA 
proteins from different subtypes of influenza. Non-neutralizing antibodies to the 
conserved epitopes on the different viral proteins such as the NP protein may play a 
role in Het-I. These antibodies could bind and help eliminate infected cells or free 
virions (Rangel-Moreno, Carragher et al. 2008). Researchers have observed 
heterosubtypic antibody responses that are non-neutralizing and are directed towards 
conserved regions of the HA molecule. These non-neutralizing, heterosubtypic HA 
specific antibodies may assist in antibody-dependent cell-mediated cytotoxicity 
and/or clearance of antigen-antibody complexes mediated by macrophages. 
Therefore, they may aid in the resolution of infection or reduction of morbidity and 
mortality (Sambhara, Kurichh et al. 2001; Goy, Von Bibra et al. 2008), and therefore 
Het-I. 
Tumpey, et al found no role for CD8+ or CD4+ T cells in their challenge studies 
using β2M-/- mice (mice that lack MHC class I) and T cell depletion studies. 
However, B cell deficient mice (IgH-6-/- mice) were not protected against 
heterosubtypic challenge. In addition, cross-reactive antibodies to the challenge virus 
were found. These results indicate a role of B cells in Het-I (Tumpey, Renshaw et al. 
2001). Others have also reported a more significant role for B cells than T cells in 
Het-I including Quan et al who found heat stable components (most likely antibodies) 
provided protection from Het-I when using inactivated influenza A virus with cholera 
toxin as an adjuvant (Quan, Compans et al. 2008).  Using a sublethal dose of a live 
virus priming followed by a heterosubtypic challenge, Nguyen et al observed B cell 




for B cells in Het-I (Nguyen, van Ginkel et al. 2001), and further showed a diversified 
antibody repertoire is also needed for Het-I (Nguyen, Zemlin et al. 2007). In contrast, 
there is the possibility that T cells and B cells together can induce Het-I. Memory T 
cells can help naïve B cells differentiate and produce new antibodies that may help 
clear the challenge infection (Rangel-Moreno, Carragher et al. 2008). 
Even with the continued analysis of Het-I, the field remains conflicted, however 
the importance of elucidating Het-I remains crucial especially after the 2009 swine-
origin pandemic and the inability of the seasonal H1N1 and H3N2 vaccine to protect 
against the pandemic virus. What would happen if a more virulent pandemic occurs in 
the future with novel HA and NA genes? While some studies have focused on the 
role of T or B cells in Het-I, others believe Het-I is multifactorial and persists despite 
knocking out or depleting one or another immune component, highlighting the 
redundancy of the immune system, which is a key strength to build upon for vaccine 
strategies. Therefore, it is possible for CD4 and CD8 T cells, non-neutralizing 
antibodies, natural killer cells, and γδ T cells to be involved. Different effectors may 
be important under different circumstances. For example in the absence of B cells, 
CD8+ and CD4+ T cells play a key role in Het-I. Experimental systems highlighting 
the contribution of particular components allow us to determine the immune 
components that are important under specific circumstances, and which components 
should be monitored in vaccine trials. Future vaccines must be designed to elicit as 
many effector mechanisms as possible in hopes of inducing Het-I and providing the 




Chapter 3: Protective efficacy and heterosubtypic immunity 
conferred by a modified live attenuated avian influenza A 
backbone in mice and ferrets 
 
*Part of this chapter was published in Hickman, D., M. J. Hossain, et al. (2008). "An avian 
live attenuated master backbone for potential use in epidemic and pandemic influenza 
vaccines." J Gen Virol 89 (Pt 11): 2682-90. 
 
3.1 Abstract 
The unprecedented emergence in Asia of multiple avian influenza virus (AIV) 
subtypes with a broad host range poses a major challenge in the design of vaccination 
strategies that are both effective and available in a timely manner. The present study 
focused on the protective effects of a genetically modified AIV as a backbone for the 
preparation of vaccines for epidemic and pandemic influenza. It has previously been 
shown that a live attenuated AIV vaccine based on the internal backbone of influenza 
A/guinea fowl/Hong Kong/WF10/99 (WF10) (H9N2), called WF10att, protects 
chickens against low- and high-pathogenic influenza strains. More importantly, this 
live attenuated virus provided effective protection when administered in ovo. In order 
to further characterize the WF10att backbone for use in epidemic and pandemic 
influenza vaccines, we evaluated its protective effects in two mammals, mice and 
ferrets, and the ability of the WF10att backbone to induce heterosubtypic immunity 
(Het-I). Het-I is the ability of one virus subtype to protect against a different subtype. 




adequate protective immunity against homologous lethal challenges with both the 
wildtype influenza A/WSN/1933 (H1N1) (WSN), mouse-adapted 
A/California/04/2009 (H1N1) (pH1N1) and A/Vietnam/1203/2004 (H5N1) (HPAI 
H5N1) viruses. C57BL/6 mice were partially protected from homologous challenge 
with HPAI H5N1. In addition, the modified attenuated virus protected ferrets against 
a homologous challenge with HPAI H5N1. Het-I was observed in mice vaccinated 
with modified attenuated virus carrying H7N2 surface proteins against both WSN and 
HPAI H5N1 challenge, and in ferrets vaccinated with the modified attenuated virus 
carrying the H9N2 surface proteins when challenged with HPAI H5N1. The results 
presented suggest that the internal genes of a genetically modified AIV confer a 
difference in Het-I depending on the surface proteins expressed and the animal model 
used. 
3.2 Introduction 
3.2.1 Live attenuated avian influenza backbone 
The emergence of highly pathogenic H5N1 avian influenza virus (AIV) in 
Asia, with an unusually broad host range and the ability to infect and kill humans, has 
raised concerns that an H5N1 virus could cause a pandemic (Horimoto and Kawaoka 
2001). Vaccines are undoubtedly a major resource that can greatly reduce the impact 
of a pandemic. Currently, two types of vaccine are commercially available for the 
prevention of seasonal influenza in the USA: inactivated split virion and live 
attenuated vaccines (Belshe 2004; Harper, Fukuda et al. 2004; Zangwill and Belshe 
2004). Murphy et al. and Subbarao et al. developed alternative approaches for the 




and human influenza A viruses (Murphy, Sly et al. 1982; Subbarao, Webster et al. 
1995; Murphy, Park et al. 1997). The main concept behind these latter approaches 
was based on the host-range restriction shown by AIVs. Thus, viruses carrying genes 
derived from an AIV would be attenuated in humans, whereas the presence of the 
human hemagglutinin (HA) and neuraminidase (NA) surface proteins would elicit a 
protective immune response against circulating influenza A viruses. These 
experimental vaccines showed great promise in pre-clinical studies and in clinical 
studies in adults and older children (Sears, Clements et al. 1988; Steinhoff, Halsey et 
al. 1990). Unfortunately, some of these vaccines caused reactions in young children 
and infants, resulting in high fever and other flu-like symptoms. In addition, the 
consistent failure to obtain some of the reassortant viruses made these approaches 
impractical (Steinhoff, Halsey et al. 1990; Steinhoff, Halsey et al. 1991).  
The advent of reverse genetics has opened up new alternatives for the 
development of live attenuated vaccines (Neumann and Kawaoka 2001). This is 
particularly important considering the unprecedented emergence of multiple strains of 
AIVs with unexpectedly broad host ranges (Capua and Alexander 2004). If one of 
these strains developed the ability to spread among a broad range of animal species, 
there would be major health, economic and ecological consequences. It is unrealistic 
to consider the preparation of multiple vaccine formulations specifically tailored for 
multiple animal species if such a strain were to emerge (Capua and Alexander 2002; 
Capua and Alexander 2004; Capua and Marangon 2004). Thus, our laboratory has 
previously analyzed an AIV backbone that has shown a broad host range, influenza 




virus vaccine donor that could be used in multiple animal species, including humans 
(Song, Nieto et al. 2007).  
H9N2 viruses of the same lineage as the WF10 virus have been shown to 
effectively infect multiple domestic poultry species, including ducks, turkeys, 
chickens and quail, as well as mice, without prior adaptation (Peiris, Yuen et al. 1999; 
Guan, Shortridge et al. 2000; Lin, Shaw et al. 2000; Peiris, Guan et al. 2001; Perez, 
Lim et al. 2003; Perez, Webby et al. 2003; Choi, Ozaki et al. 2004; Xu, Fan et al. 
2004). Viruses phylogenetically related to the WF10 virus have also been isolated 
from pigs (Xu, Fan et al. 2004), and we have shown that the WF10 virus has many 
biological features similar to human influenza viruses, including the ability to infect 
non-ciliated cells in cultures of human airway epithelial cells (Wan and Perez 2007). 
Thus, WF10 potentially represents an ideal candidate for the preparation of live 
vaccines applicable to multiple animal species.  
3.2.2 Heterosubtypic immunity 
In June 2009, the WHO declared the swine-origin H1N1 virus a new 
pandemic (WHO 2011). With the threat of this and future pandemics looming, there 
is a need to develop vaccines that are able to protect against multiple subtypes of 
influenza viruses. Het-I will not prevent infection but will result in earlier clearance 
of the virus (Yetter, Lehrer et al. 1980),  and reduced morbidity, mortality, and 
transmission. In order to develop these vaccines, we need to further understand the 
underlying mechanisms of Het-I and the induction of these immune mechanisms 
through vaccination. Although Het-I has been studied for several decades in animals 




cells in Het-I remains unclear. Most studies have focused on the ability of natural 
infections to induce heterosubtypic immunity (Schulman and Kilbourne 1965; Yetter, 
Barber et al. 1980; Yetter, Lehrer et al. 1980; Liang, Mozdzanowska et al. 1994; 
Epstein, Lo et al. 1997; Benton, Misplon et al. 2001; Nguyen, van Ginkel et al. 2001; 
Droebner, Haasbach et al. 2008; Kreijtz, Bodewes et al. 2009) or inactivated vaccines 
with or without adjuvants (McLaren and Potter 1974; Quan, Compans et al. 2008; 
Alsharifi, Furuya et al. 2009), but few studies have analyzed the ability of live 
attenuated influenza vaccines containing different surface glycoproteins to induce 
Het-I. In addition, many studies have focused on the same influenza virus 
subtypes/strains and their ability to induce Het-I, which include A/Puerto Rico/8/34 
(H1N1) (PR8) and X31 strain (a reassortant strain containing the internal genes from 
PR8 and the surface genes from A/Aichi/2/68 (H3N2)). Therefore, it is important to 
determine whether the conclusions formed from these studies are consistent for other 
strains of influenza. 
In previous studies, we showed that the WF10att backbone was attenuated in 
birds and provided protection against both a low- and high-pathogenic challenge 
(Song, Nieto et al. 2007). In this study, we expand on the characterization of the 
genetically modified WF10att backbone in mammals, mice and ferrets. Our results 
show that genetically modified WF10att backbone induced protective immunity 
against the homologous challenge with lethal H1N1 or HPAI H5N1 in Balb/c mice, 
C57BL/6 and ferrets. Furthermore, Het-I was induced in both the mouse and ferret 
models. However, there was a difference in Het-I depending on the surface proteins 




potential of a genetically modified AIV backbone as a donor for influenza vaccines 
for avian and mammalian species.   
3.3 Materials and methods 
3.3.1 Cells and viruses 
 Human embryonic kidney 293T and Madin–Darby canine kidney (MDCK) 
cells were maintained as described previously (Song, Nieto et al. 2007). The WF10 
and the mouse-adapted influenza A/WSN/1933 (H1N1) (WSN) viruses were kindly 
provided by Dr. Robert Webster, St Jude Children’s Research Hospital, Memphis, 
TN, USA. The highly pathogenic AIV A/Vietnam/1203/2004 (H5N1) (HPAI H5N1) 
was obtained from the repository at the Centers for Disease Control and Prevention, 
Atlanta, GA, USA. The A/chicken/Delaware/VIVA/2004 (H7N2) virus was kindly 
provided by Dr. Dennis Senne, National Veterinary Services Laboratory, APHIS-
USDA, Ames, IA, USA. The mouse-adapted pandemic A/California/04/2009 
(pH1N1) was created first by intranasally infecting DBA/J2 with wildtype Ca/04 
virus (5.4 x 105 TCID50). Lungs were collected from the infected DBA/J2 mice and 
were homogenized in PBS with antibiotics. After centrifugation at 6,000 rpm for 10 
min, 50µl of supernatant from the homogenate was used to infect naive Balb/c mice. 
Lungs from these infected Balb/c mice were then homogenized and inoculated into 
MDCK cells to prepare the pH1N1 virus stock. Stock virus titers were measured by 
plaque assay on MDCK cells at 37°C or 32°C or by 50% egg infectious dose (EID50) 
as described previously (Reed 1938). All studies using HPAI H5N1 virus were 
performed in an enhanced Biosafety Level 3 plus (BSL-3+) facility approved by the 




3.3.2 Generation of recombinant viruses by reverse genetics 
The H7 and N2 genes of the H7N2 virus, ΔH5 (deletion of polybasic amino 
acids of the cleavage site) and N1 genes of the HPAI H5N1 virus, and the H1 and N1 
genes of pH1N1 were cloned as described by Song et al. (Song, Nieto et al. 2007). 
Recombinant viruses were generated by transfection of plasmid DNA into co-cultured 
293T and MDCK cells as described previously (Hoffmann, Neumann et al. 2000). 
Recombinant virus stocks were amplified in the allantoic cavity of 10-day-old 
embryonated chicken eggs. The pH1N1 vaccine virus was serially passaged in eggs 
seven times to increase the stock titer. For each virus, RT-PCR and full-length 
sequencing were performed for each viral segment to verify their identity. Sequences 
were generated using specific primers, Big Dye Terminator v3.1 Cycle Sequencing 
kit (Applied Biosystems, Calsbad, CA) and a 3100 Genetic Analyzer (Applied 
Biosystems, Calsbad, CA), according to the manufacturer’s instructions. 
3.3.3 Immunization and challenge of mice 
  To evaluate the protective capacity of the recombinant vaccines, ΔH5N1att, 
H7N2att, and H9N2att, five-week-old female specific pathogen free (SPF) BALB/c 
or C57BL/6 mice (National Cancer Institute (NCI), Fredrick, MD) were anesthetized 
with isofluorane administered using Vetequip mobile anesthesia system (Vetequip, 
Inc, Pleasanton, CA). Then the mice were immunized intranasally (i.n.) with 106 PFU 
of WSN H1N1att, or 106 EID50 of ΔH5N1att, H7N2att, or H9N2att, or 106 TCID50 of 
pH1N1att in 50µl PBS; all mock-immunized mice received 50µl PBS. On day 3-post 
vaccination, six mice per vaccine group were anesthetized with isofluorane and 




homogenized in PBS, and stored at -70ºC until processed.  Virus titers in lung 
homogenates were determined by EID50 at 35ºC. For the remaining 3 mice in each 
group, lungs were inflated inside the mouse cavity (in-situ) with 10% neutral buffered 
formalin (VWR, Radnor, PA) and dropped in formalin for histology. A certified 
pathologist examined all slides and generated a report and images.  
The 50% mouse lethal dose (MLD50) for the challenge viruses, WSN, pH1N1, 
and HPAI H5N1, was calculated using groups of four mice inoculated i.n. with virus 
doses ranging from 100 to 106 PFU, EID50, or TCID50. The Reed and Muench method 
was used to calculate the MLD50 (Reed 1938). Clinical signs, body weight and 
mortality of mice were monitored and recorded for 14 or 21 days.  
To assess vaccine efficacy, at 21 days post vaccination (dpv), all the 
immunized mice were anesthetized with isofluorane and challenged i.n. with 20 
MLD50 in 50µl PBS of WSN, HPAI H5N1, or 100 MLD50 pH1N1 virus. At 3, 6, 9, or 
12 days post challenge (dpc), 3 mice per group were sacrificed, and lungs were 
collected to measure virus titers.  Lung homogenates were prepared in PBS and 
frozen at -70ºC until processed. Virus titers in lung homogenates were determined by 
TCID50 on MDCK cells at 37ºC, and titers were determined using the Reed and 
Muench method. At 9 dpc, 3 mice per group were sacrificed, and lungs were inflated 
inside the mouse cavity (in-situ) with 10% neutral buffered formalin (VWR, Radnor, 
PA) and dropped in formalin for histology. A certified pathologist examined all slides 
and generated a report and images. Animal studies using WSN were performed under 
BSL-2 conditions; studies using pH1N1 were performed under BSL-2+ conditions. 




approval. All animal experiments were performed according to protocols approved by 
the Institutional Animal Care and Use Committee of the University of Maryland, 
College Park. 
3.3.4 Immunization and challenge of ferrets 
 Four-month-old female Fitch ferrets (Mustela putorius furo) (Triple F Farms, 
Sayre, PA) were lightly anesthetized with ketamine (20 mg/kg) and xylazine (1 
mg/kg) via an intramuscular injection before vaccination and challenge. A 
subcutaneous temperature transponder (Bio Medic Data Systems, Seaford, DE) was 
placed in each ferret for identification and temperature readings. Temperatures were 
recorded daily post vaccination and post challenge. Ferrets (5 per group) were 
inoculated i.n. with 106 EID50 or TCID50/ferret of recombinant vaccines in 0.5 mL 
PBS, 0.25 mL per nostril.  All mock-immunized ferrets received 0.25 mL of PBS per 
nostril. Nasal washes were taken on days 1, 3, 5, and 7-post vaccination to titer 
vaccine viruses in the upper respiratory tract of the ferret.  Three days post 
vaccination (dpv), three ferrets per group were sacrificed and lungs were collected to 
titer the vaccine virus.  Vaccine viral titers were determined by TCID50 on MDCK 
cells at 37ºC. Nasal washes were collected by anesthetizing the ferrets as described 
above and 0.5 mL of PBS was expelled into each nostril to induce sneezing onto a 
petri dish.  Blood was drawn on days 0, 7, 14, and 21-post vaccination.   
 Twenty-one dpv, the remaining two ferrets were infected with 2x105 PFU of 
HPAI H5N1 because this dose is lethal in ferrets by 9 dpi (Mahmood, Bright et al. 
2008). On days 1, 3, 5, and 7-post challenge, nasal washes were collected and blood 




in a total volume of 1 mL and frozen at -70ºC until processed. Virus titers in nasal 
washes were determined by TCID50 on MDCK cells at 37ºC using the Reed and 
Muench method. Clinical signs, body weight and mortality of ferrets were monitored 
daily and recorded for 14 dpc. Three independent ferret challenge experiments were 
performed totaling six ferrets per group; two ferrets were challenged in each 
experiment.  Animal studies using HPAI H5N1 were performed under BSL-3+ 
conditions with USDA approval.  Animal studies were performed according to 
protocols approved by the Institutional Animal Care and Use Committee of the 
University of Maryland, College Park. 
3.4 Results 
3.4.1 Genetically modified WF10att viruses are attenuated in both Balb/c and 
C57BL/6 mice 
A/Ann Arbor/6/60 (H2N2) strain is the master donor strain for live attenuated 
influenza A viruses (MDV-A) currently in clinical use. The temperature sensitive (ts) 
phenotype of influenza has been mapped to three amino acid mutations in PB1 
(K391E, E581G, A661T), one in PB2 (N265S), and one in NP (D34G) (Jin, Zhou et 
al. 2004). We previously showed that the ts loci in the PB2 and PB1 genes of the 
MDV-A strain can be transferred to the WF10 backbone producing a similar ts 
phenotype (Song, Nieto et al. 2007) and that the addition of an HA tag at the C-
terminus of the PB1 gene provided an attenuated (att) phenotype in chickens and 
quail. To further characterize the biological properties of attenuated viruses using the 
WF10att backbone and to determine their potential as a universal master donor strain 




WF10att internal genes carrying different surface glycoproteins as follows: H1N1 
from WSN or pH1N1, ΔH5N1 from HPAI H5N1 (deletion of the poly basic cleavage 
site), H7N2 from A/chicken/Delaware/04, and H9N2 from WF10 (Table 2). We 
rescued five recombinant viruses, called 2H1N1:6WF10att from WSN or pH1N1, 
2ΔH5N1:6WF10att, 2H7N2:6WF10att, and 2H9N2:6WF10att. All virus names were 




















  Table 2. Recombinant Vaccines 
Surface Backbone Abbreviation 
2H1N1:6WF10atta WF10att WSN H1N1att 
2pH1N1:6WF10attb WF10att pH1N1att 
2ΔH5N1:6WF10attc WF10att ΔH5N1att 
2H7N2:6WF10attd WF10att H7N2att 
2H9N2:6WF10atte WF10att H9N2att 
 
 
Surface proteins (HA and NA) from 
aA/WSN/1933 (H1N1)  
bMouse-adapted A/California/04/2009 (pH1N1)  
Egg passage 7 (P7)  
cA/Vietnam/1203/2004 (HPAI H5N1)  
dA/chicken/Delaware/VIVA/2004 (H7N2)  






 Five-week-old Balb/c and C57BL/6 mice were i.n. inoculated with recombinant 
vaccines in 50µl of PBS.  pH1N1att P1 grows very slowly, therefore the virus had to 
be passaged six times in eggs creating pH1N1att P7 stock. Serial passaging the 
vaccine increased the titer such that mice could be inoculated with 106 TCID50. On day 
3-post vaccination, 3 mice per group were sacrificed, and lungs were collected to titer 
the vaccine virus (Table 3 and Table 4). Only pH1N1att and H7N2att were detected in 
the lungs of Balb/c mice (Table 3) while both H7N2att and H9N2att were detected in 
the lungs of C57BL/6 mice (Table 4). Also at 3 dpv, 3 mice per group were sacrificed, 
and lungs were prepared for histology (Figures 2 and 3). Only mild lung pathology 
was observed in the lungs of the vaccinated Balb/c and C57BL/6 mice. ΔH5N1att 
caused lymphocyte cuffing in the lungs of both Balb/c and C57BL/6 mice while 
H7N2att caused hyperplasia resulting in inflammation in Balb/c mice lungs.  Both 
H7N2att and H9N2att caused bronchiolar necrosis in the C57BL/6 mice; H9N2att 
caused lymphocyte cuffing in Balb/c mice (Figures 2 and 3). The mice were 
monitored for 21 dpv for body weight loss and clinical signs, and no disease signs 
were observed indicating that the vaccines were attenuated in both strains of mice, 






Table 3. Replication of Recombinant vaccines in lungs of Balb/c mice. 
Vaccine 
Immunization dose 
(PFUb/, TCID50c/, or 
EID50d/mouse) 
Titer in log10 EID50/g at 3 
dpv 
PBS Control -- BLDe 
WSN H1N1att 106a BLDe 
pH1N1att P7a 106b 4.9±0.5 
ΔH5N1att 106c BLDe 
H7N2att 106c 2.8±0.8 
H9N2att 106c BLDe 
 
aP7 is egg passage 7  







Table 4. Replication of recombinant vaccines in the lungs of C57BL/6 mice. 
Vaccine Immunization dose (EID50/mouse) 
Titer in log10 EID50/g at 3 
dpv 
PBS Control -- BLDa 
ΔH5N1att 106 BLDa 
H7N2att 106 3.8±1.6 
H9N2att 106 1.8±1.6 
 







Figure 2. Histology of Balb/c mouse lung tissue at 3 dpv. Five-week-old female 
Balb/c mice were immunized with 106 EID50 in 50µl PBS of ΔH5N1att, H7N2att, or 
H9N2att. Control mice received 50µl PBS. At 3 dpv, lungs were collected for 
histology. No obvious pathology was found with the (A) PBS control mice.  Only mild 
pathology was found after immunization with the different vaccines. With the (B) 
ΔH5N1att immunized mice lymphocyte cuffing was observed, with (C) H7N2att 
immunized mice mild inflammation was observed, and with (D) H9N2att immunized 









Figure 3. Histology of C57BL/6 mouse lungs at 3 dpv. Five-week-old female Balb/c 
mice were immunized with 106 EID50 in 50µl PBS of ΔH5N1att, H7N2att, or 
H9N2att. Control mice received 50µl PBS. At 3 dpv, lungs were collected for 
histology. No pathology was found with the (A) PBS control mice.  Only mild 
pathology was found after immunization with the different vaccines. With the (B) 
ΔH5N1att immunized mice lymphocyte cuffing was observed, with (C) H7N2att 
immunized mice mild bronchiolar necrosis was observed, and with (D) H9N2att 











3.4.2 The WF10att backbone protects Balb/c mice against lethal H1N1 challenge 
 Five-week-old Balb/c and C57BL/6 mice were i.n. inoculated with vaccine 
viruses and control mice received PBS (Figure 4).  Twenty-one days post vaccination, 
all mice were challenged with 20 MLD50 of WSN virus.  The mice were monitored 
for 21 days post challenge for disease signs including decrease in body weight 
(Figure 5), lack of grooming, decrease in activity, respiratory signs, and dehydration. 
At 3 and 6 dpc, 3 mice per group were sacrificed and virus titers in the lungs were 
determined by TCID50 (Table 5). The mice vaccinated with WSN H1N1att were 
completely protected from lethal challenge (Figure 5). No disease signs or decrease in 
body weight were observed. In addition, no challenge virus was detected in the lungs 
at either 3 or 6 dpc (Table 5). Both the H7N2att and H9N2att vaccinated mice 
showed body weight loss and displayed mild to moderate disease signs. The H7N2att 
vaccinated mice lost more body weight (~15%) and had more pronounced disease 
signs including lack of grooming and slight hunched posture, while the H9N2att 
vaccinated mice showed a lack of grooming (Figure 5).  Both H7N2att and H9N2att 
vaccinated mice had similar levels of challenge virus in the lungs at 3 dpc, however 
both groups of vaccinated animals were able to clear the challenge virus from the 
lungs by 6 dpc (Table 5). All vaccinated mice survived lethal challenge with WSN 
indicating that the WF10att backbone induces both homotypic and heterosubtypic 







Figure 4. Mouse Vaccination Strategy. Five-week-old female Balb/c or C57BL/6 
mice were vaccinated i.n. with 106 EID50 of ΔH5N1att, H7N2att, or H9N2att vaccine 
in 50µl PBS. Controls received 50µl of PBS.  Mice were bled on day 0 and 21 post 
vaccination to collect sera. Twenty-one days post vaccination, mice were challenged 
with 20 MLD50 of WSN, HPAI H5N1, or 100 MLD50 pH1N1.  Three mice per group 
were anesthetized and sacrificed by cervical dislocation at 3, 6, 9, or 12 dpc as 
indicated to titer the challenge virus in the lungs. Mice were monitored for disease 











Figure 5. Percent body weight loss in vaccinated Balb/c mice challenged with 
A/WSN/1933 (H1N1). Vaccinated female Balb/c mice were challenged with 20 
MLD50 of lethal WSN virus. All control mice died or had to be humanely sacrificed 
by 8 dpc. WSN H1N1att vaccinated mice did not lose body weight and displayed no 
disease signs post challenge. H9N2att vaccinated mice lost less than 5% of their body 
between days 3-6 post challenge, however they were able to regain the weight and 
displayed mild disease signs. H7N2att vaccinated mice lost 15% of their body weight 
and displayed moderate disease signs. All vaccinated mice survived the lethal WSN 




















Table 5. Clearance of A/WSN/33 (H1N1) challenge virus in the lungs of Balb/c 




dose (PFUa or 
EID50b/mouse) 
Challenged 
with 20 MLD50 
of 
Challenge virus 
titer in log10 
(PFUa or 
TCID50c)/g at 3 
dpc 
Challenge virus 
titer in log10 
(PFUa or 
TCID50c)/g at 6 
dpc 
PBS -- WSN 6.1±0.1c 5.4±0.4c 
WSN H1N1att 106a WSN BLDa,d BLDa,d 
H7N2att 106b WSN 5.9±0.7c BLDc,d 
H9N2att 106b WSN 5.1±0.1c BLDc,d 
 







Although all vaccinated Balb/c mice were protected against lethal WSN 
challenge, we sought to determine if this finding was strain specific. WSN is a 
laboratory strain that is highly adapted to mice.  Thus, we examined if the WF10att 
backbone would induce both homotypic and heterosubtypic immunity when a more 
contemporary challenge virus was used at a higher dose. To address this hypothesis, 
we vaccinated 5-week-old female Balb/c mice with 106 TCID50 or EID50 of 
pH1N1att, H7N2att, or H9N2att in 50µl PBS. Control mice received 50µl PBS. 
Twenty-one days post vaccination, all mice were challenged with 100 MLD50 of 
pH1N1. On days 3 and 6 post challenge, 3 mice per group were sacrificed to titer the 
challenge virus in the lungs (Table 6). Similar to our findings with WSN, all 
vaccinated mice survived pH1N1 challenge.  The H1N1att vaccinated mice lost less 
than 10% of their body weight and showed a lack of grooming; however, these mice 
regained their body weight by 10 dpc and survived (Figure 6). A small amount of 
challenge virus was detected in the lungs at 3 dpc although by 6 dpc no virus was 
isolated from the lungs (Table 6). Both the H7N2att and H9N2att vaccinated mice 
lost greater than 15% of their body weight by 6 dpc and displayed disease signs 
including a lack of grooming, respiratory symptoms, and inactivity.  Also virus titers 
similar to the control mice were detected in the lungs of both groups at 3 dpc. By 6 
dpc, both the H7N2att and H9N2att mice reduced the challenge virus in the lungs 
(Table 6) and survived challenge (Figure 6). These results indicate that the WF10att 
backbone is able to induce homotypic and heterosubtypic immunity when challenged 






Figure 6. Percent body weight loss in vaccinated Balb/c mice challenged with 
Mouse-adapted A/California/04/2009 (pH1N1). Vaccinated female Balb/c mice 
were challenged with 100 MLD50 of pH1N1. pH1N1att vaccinated mice lost less than 
10% of their body and displayed mild disease signs including lack of grooming. Both 
H7N2att and H9N2att vaccinated mice lost approximately 20% of their body weight 
and displayed moderate disease signs including rough coat, hunched posture and 
inactivity. All control mice died or had to be humanely sacrificed by 10 dpc, while all 





















Table 6. Clearance of Mouse-adapted A/California/04/2009 (pH1N1) challenge 









Titer in log10 
TCID50/g at 3 
dpc 
Titer in log10 
TCID50/g at 6 
dpc 
PBS Control 106 pH1N1 5.7±0.3 6.0±0.3 
pH1N1att P7a 106 pH1N1 1.6±0.5 BLDb 
H7N2att 106 pH1N1 5.7±0.5 3.6±0.7 
H9N2att 106 pH1N1 6.0±0.2 4.3±1.1 
 
aP7 is egg passage 7 







3.4.3 Surface glycoproteins influence the degree of heterosubtypic immunity 
conferred to Balb/c mice vaccinated by WF10att backbone upon HPAI H5N1 
challenge  
Since the WF10att backbone induced both homotypic and heterosubtypic 
immunity during H1N1 challenges, we wanted to determine if the same is true for a 
different subtype, HPAI H5N1. The emergence of HPAI H5N1 virus in Asia, with an 
unusually broad host range and the ability to infect and kill people, has raised 
concerns that it may cause a pandemic. Therefore, five-week-old female Balb/c mice 
were vaccinated i.n. with 106 EID50 of ΔH5N1att, H7N2att, or H9N2att in 50µl PBS; 
control mice received 50µl of PBS. Twenty-one days post vaccination, all mice were 
challenged with 20 MLD50 of HPAI H5N1. On days 6, 9, and 12 post challenge, 3 
mice per group were sacrificed to titer the challenge virus in the lungs. As observed 
previously, mice vaccinated with ΔH5N1att, lost less than 5% of their body weight 
and displayed few disease signs.  Only a lack of grooming was observed between 4-7 
dpc.  By 8 dpc, mice regained their body weight and survived challenge (Figure 7). 
These mice had high titers of challenge virus in the lung at 6 dpc, however they were 
able to clear the challenge virus by 9 dpc (Table 7). The H7N2att mice lost 10% of 
their body weight and displayed disease signs including a rough coat, hunched 
posture, and respiratory signs between 4-10 dpc. These vaccinated mice were able to 
regain their body weight and survived challenge (Figure 7). The H7N2att mice also 
had high titers of challenge virus in their lungs at 6 dpc, however one mouse was able 
to clear the challenge virus by 9 dpc and the other mice were able to clear the 




losing weight at 4 dpc and displayed disease signs including rough coat, hunched 
posture, inactivity, labored breathing, dehydration, and some mice displayed 
neurological signs until they succumbed to the infection by 13 dpc (Figure 7). These 
animals had high levels of challenge virus in the lungs until death (Table 7).  
These data were corroborated with the histology data (Figure 8). PBS controls 
had interstitial lesions in addition to bronchiolar necrosis while ΔH5N1att immunized 
mice had mild pathology with lymphocyte cuffing; however, the bronchioles and 
alveoli were normal (Figure 8). Although the H7N2att immunized mice were 
protected from challenge, these mice displayed lung pathology including lymphocyte 
cuffing, bronchiolar necrosis, hyperplasia, and interstitial inflammation. The H9N2att 
immunized mice had severe lung pathology including lymphocyte cuffing and 
interstitial inflammation consistent with the high viral titers detected post challenge 
(Table 7). Therefore, there was a clear difference in the degree of heterosubtypic 
immunity with HPAI H5N1 challenge; all the H7N2att vaccinated mice survived 







Figure 7. Percent body weight loss in vaccinated Balb/c mice challenged with 
A/Vietnam/1203/2004 (HPAI H5N1). Vaccinated female Balb/c mice were 
challenged with 20 MLD50 of HPAI H5N1 virus at 21 dpv. All control mice died or 
had to be humanely euthanized by 10 dpc. The ΔH5N1att immunized mice did not 
lose body weight and displayed no disease signs. The H7N2att immunized mice lost 
10% of their body weight and displayed disease signs including rough coat, hunched 
posture, and respiratory signs between days 4-10 post challenge. The H9N2att 
immunized mice began losing weight at 4 dpc and continued until death, which 
occurred by 13 dpc. These mice also displayed disease signs including rough coat, 
hunched posture, inactivity, labored breathing, dehydration, and neurological signs. 




















Table 7. Clearance of A/Vietnam/1203/2004 (HPAI H5N1) challenge virus in the 






Titer in log10 
TCID50/lung 
at 6 dpc 
Titer in log10 
TCID50/g at 9 
dpc 
Titer in log10 
TCID50/g at 
12 dpc 
PBS Control HPAI H5N1 7.1±0.3 5.3±0.1 -- 
ΔH5N1att HPAI H5N1 4.9±0.1 BLD BLD 
H7N2att HPAI H5N1 5.1±0.3 2.2±0.0* BLD 
H9N2att HPAI H5N1 5.7±0.3 5.2±0.0 -- 
   
*One mouse was able to clear the challenge virus completely 










Figure 8. Histology of Balb/c mouse lung tissue at 9 dpc. Five-week-old female 
Balb/c mice were immunized with 106 EID50 in 50µl PBS of ΔH5N1att, H7N2att, or 
H9N2att. Control mice received 50µl PBS. At 21 dpv, mice were challenged with 20 
MLD50 of HPAI H5N1. At 9 dpc, lungs were collected for histology. (A) PBS 
controls had interstitial lesions in addition to bronchiolar necrosis.  (B) ΔH5N1att 
immunized mice had mild pathology with lymphocyte cuffing observed, however the 
bronchioles and alveoli were normal. (C) H7N2att immunized mice displayed 
lymphocyte cuffing, bronchiolar necrosis, hyperplasia, and interstitial inflammation, 
and (D) H9N2att immunized mice displayed lymphocyte cuffing and interstitial 












3.4.4 Surface glycoproteins influence the degree of heterosubtypic immunity 
conferred to C57BL/6 mice vaccinated with WF10att backbone and challenged 
with HPAI H5N1 
After observing a difference in the protection induced by the WF10att 
backbone expressing different surface proteins in Balb/c, we sought to determine if 
this finding was mouse strain specific. Furthermore, as an initial step towards 
determining the mechanism of heterosubtypic immunity, we vaccinated and 
challenged C57BL/6 mice because most immune deficient knockout mice are in the 
C57BL/6 background. The same vaccination and challenge strategy used for the 
Balb/c mice was used for the C57BL/6 mice (Figure 4). Interestingly, only 50% of the 
homotypically challenge C57BL/6 mice were completely protected from challenge 
although these mice had similar levels of virus in the lung as Balb/c mice (Figure 9 
and Table 8). In regards to the heterosubtypic challenged mice, the H7N2att 
vaccinated mice were slightly more protected than the H9N2att vaccinated mice 
(Figure 9).  Both groups of mice had high levels of challenge virus in the lungs at 3 
and 6 dpc (Table 8).  
These results are consistent with the histology data (Figure 10). PBS controls 
displayed lymphocyte cuffing, bronchiolar necrosis, fibrin, and interstitial 
inflammation.  While the ΔH5N1att immunized mice, which had some level of 
protection, displayed mild pathology with lymphocyte cuffing observed, however the 
bronchioles and alveoli were normal. H7N2att immunized mice displayed 
lymphocyte cuffing and interstitial inflammation, and H9N2att immunized mice 
displayed lymphocyte cuffing, bronchiolar hyperplasia and necrosis, and alveolar 




genetic background of the host, as the H7N2att surface protected Balb/c mice, but did 
not induce high levels of heterosubtypic immunity in C57BL/6 mice.  However, the 
ΔH5N1att vaccine did provide 50% protection (Figure 9b). In C57BL/6 mice similar 
to Balb/c mice, the H7N2att vaccinated mice had increased survival when compared 
to H9N2att vaccinated mice challenged with HPAI, suggesting a difference in 
heterosubtypic immunity in C57BL/6 mice. Given the degree of heterosubtypic 
immunity was different in two mice strains, we questioned whether this phenotype 







Figure 9. Percent body weight and percent survival of vaccinated C57BL/6 mice 
challenged with A/Vietnam/1203/2004 (HPAI H5N1). Vaccinated female C57BL/6 
mice were challenged with 20 MLD50 of HPAI H5N1. (A) Percent body weight loss. 
The ΔH5N1att immunized mice lost approximately 15% of their body weight and 
only 50% of the mice were able to regain the weight and survived challenge. The 
H7N2att immunized mice lost 20% of their body weight and 25% were able to regain 
the weight and survived. The H9N2att immunized mice also lost 20% of their body 
weight and 19% of these mice survived. All control mice died or were humanely 
euthanized by 8 dpc. Data represents two independent experiments. (B) Percent 
survival. Fifty percent of the ΔH5N1att immunized mice were protected against 
homotypic challenge with HPAI H5N1. Twenty-five percent of H7N2att immunized 
mice survived challenge while only 19% of H9N2att immunized mice survived 





Table 8. Clearance of A/Vietnam/1203/2004 (HPAI H5N1) challenge virus in the 









Titer in log10 
TCID50/g at 3 
dpc 
Titer in log10 
TCID50/g at 6 
dpc 
PBS Control -- HPAI H5N1 4.7±0.6 6.2±0.0 
ΔH5N1att 106 HPAI H5N1 4.5±1.2 3.4±0.7 
H7N2att 106 HPAI H5N1 4.9±0.3 4.7±0.6 



































Figure 10. Histology of C57BL/6 mouse lung tissue at 9 dpc. Five-week-old female 
C57BL/6 mice were immunized with 106 EID50 in 50µl PBS of ΔH5N1att, H7N2att, 
or H9N2att. Control mice received 50µl PBS. At 21 dpv, mice were challenged with 
20 MLD50 of HPAI H5N1. At 9 dpc, lungs were collected for histology. (A) PBS 
controls displayed lymphocyte cuffing, bronchiolar necrosis, fibrin, and interstitial 
inflammation.  (B) ΔH5N1att immunized mice had mild pathology with lymphocyte 
cuffing observed, however, their bronchioles and alveoli were normal. (C) H7N2att 
immunized mice displayed lymphocyte cuffing and interstitial inflammation and (D) 
H9N2att immunized mice displayed lymphocyte cuffing, bronchiolar hyperplasia and 














3.4.5 Boost dose protects Balb/c mice against HPAI challenge 
After observing a difference in the protection induced by the WF10att 
backbone expressing different surface proteins in Balb/c, we sought to determine if a 
boost dose of WF10att would protect the H9N2att immunized mice from HPAI 
H5N1 challenge. Balb/c mice were immunized with 106 EID50 of ΔH5N1att, 
H7N2att, or H9N2att in 50µl PBS. Control mice received 50µl PBS. At 21 dpv, all 
mice received a second dose of 106 EID50 of each vaccine or PBS for controls. At 21 
days after the boost dose, mice are challenged i.n. with 20 MLD50 of HPAI H5N1. On 
days 3 and 6 post challenge, 3 mice per group were sacrificed to titer the challenge 
virus in the lungs. Mice vaccinated with two doses of ΔH5N1att lost no body weight, 
displayed no disease signs post challenge, and survived challenge (Figure 11). These 
mice had high titers of challenge virus in the lung at 3 dpc; however, they were able 
to reduce the challenge virus by 6 dpc (Table 9). The H7N2att mice lost less than 5% 
of their body weight and displayed mild disease signs including lack of grooming 
between 5-9 dpc. These vaccinated mice were able to regain their body weight and 
survived challenge (Figure 11). The H7N2att mice also had high titers of challenge 
virus in their lungs at both 3 and 6 dpc (Table 9). Surprisingly, the H9N2att 
vaccinated mice lost about 15% of their body weight and displayed disease signs 
including rough coat, hunched posture, and respiratory signs. However with two 
doses of vaccine, the animals were able to regain their body weight and survived 
challenge (Figure 11). These animals had similar levels of challenge virus in their 
lungs as the H7N2att vaccinated mice.  The results show that two doses of vaccine 






Figure 11. Percent body weight of Balb/c mice vaccinated with two doses of 
recombinant vaccine and challenged with A/Vietnam/1203/2004 (HPAI H5N1). 
Mice vaccinated with two doses of ΔH5N1att lost no body weight, displayed no 
disease signs post challenge, and survived challenge. The H7N2att mice lost less than 
5% of their body weight and displayed mild disease signs including lack of grooming 
between 5-9 dpc. These vaccinated mice were able to regain their body weight and 
survived challenge. Surprisingly, the H9N2att vaccinated mice lost about 15% of 
their body weight and displayed disease signs including rough coat, hunched posture, 
and respiratory signs. However with two doses of vaccine, the animals were able to 




















Table 9. Clearance of A/Vietnam/1203/2004 (HPAI H5N1) challenge virus in the 
lungs of Balb/c mice immunized with two doses of recombinant vaccines.  
 




Titer in log10 
TCID50/gram at 3 
dpc 
Titer in log10 
TCID50/gram at 
6 dpc 
PBS Control -- HPAI H5N1 5.7±0.3 7.2±0.04 
ΔH5N1att 106 HPAI H5N1 6.8±0.2 2.3±0.1 
H7N2att 106 HPAI H5N1 5.8±0.2 5.8±0.8 





3.4.6 Genetically modified WF10att viruses are attenuated in ferrets. 
Since we observed a difference in heterosubtypic immunity in both Balb/c and 
C57BL/6 mice, we wanted to determine if our WF10att backbone would also induce 
a difference in heterosubtypic immunity in ferrets. Importantly, the ferret model of 
influenza closely resembles influenza infection in humans. The definition of an att 
virus is the lack of replication in the lungs of ferrets; however, replication is detected 
in the upper respiratory tract where the temperature is lower. Therefore, ferrets were 
vaccinated with 106 EID50 or TCID50 of ΔH5N1att, H7N2att, or H9N2att vaccine 
viruses in 0.5 mL PBS; controls animals received 0.5 mL PBS (Figure 12). At 3 dpv, 
3 ferrets per group were sedated with a mixture of xylazine and ketamine and 
sacrificed. Lungs were collected and vaccine virus was titered by TCID50.  None of 
the vaccine viruses were detected in the lung of ferrets 3 dpv indicating that our 
WF10att backbone is attenuated regardless of the surface protein subtype expressed. 
At 1, 3, 5, and 7 dpv, nasal washes were taken to titer the vaccine viruses in the upper 
respiratory tract of ferrets. ΔH5N1att was not detected in the nasal washes at any day 
post vaccination, while both H7N2att and H9N2att replicated to high titers in the 
upper respiratory tract (Figure 13). Although some of the recombinant vaccines 
replicated to high titers in the upper respiratory tract of ferrets, no clinical signs were 








Figure 12. Ferret Vaccination Strategy. Four-five month old female ferrets (2 per 
group) were immunized i.n. with 106 EID50 or TCID50/ferret of recombinant vaccines 
in 0.5 mL PBS, 0.25 mL per nostril.  All mock-immunized ferrets received 0.25 mL 
of PBS per nostril. Nasal washes were taken on days 1, 3, 5, and 7-post vaccination to 
titer vaccine viruses in the upper respiratory tract of the ferret.  Blood was drawn on 
days 0, 7, 14, and 21 post vaccination.  Twenty-one dpv, ferrets were infected with 
2x105 PFU of HPAI H5N1. On days 1, 3, 5, and 7-post challenge, nasal washes were 
collected to titer the challenge virus. Blood was taken on days 7 and 14-post 
challenge.  Clinical signs, body weight and mortality of ferrets were monitored and 
recorded for 14 dpc. Three independent ferret vaccine experiments were performed 






Figure 13. Replication of recombinant vaccines in nasal washes (upper 
respiratory tract) of ferrets. Ferrets were vaccinated i.n. with ΔH5N1att, H7N2att, 
or H9N2att in 0.5 mL PBS. On days 1, 3, 5, and 7-post vaccination, nasal washes 
were collected and vaccine virus was titered by TCID50. The ΔH5N1att vaccine was 
not detected in the nasal wash of ferrets at any day post vaccination. Both H7N2att 
and H9N2att were detected on 1, 3, and 5 days post vaccination and were cleared by 
7 dpv. Data combined from three independent experiments.  Data are mean ± SD of 



















3.4.7 Surface glycoproteins influence the degree of heterosubtypic immunity 
conferred to ferrets vaccinated with WF10att backbone upon HPAI H5N1 
challenge. 
 Although two of the vaccine viruses replicated to high titers in the upper 
respiratory tract of ferrets, no virus was detected in the lungs and no clinical signs 
were observed for 21 dpv.  Therefore, given this attenuated phenotype we next 
evaluated the protective capacity of our WF10att backbone in ferrets. Three 
independent experiments were performed with 2 ferrets per group for a total of 6 
ferrets per group. At 21 dpv, ferrets were challenged i.n. with a lethal dose of 2 x 105 
PFU of HPAI H5N1 virus in 0.5 mL PBS. On days 1, 3, 5, and 7-post challenge, 
nasal washes were performed to titer the challenge virus. Ferrets were observed for 
clinical signs for 14 dpc. The ΔH5N1att vaccinated ferrets survived challenge (Figure 
14b) and lost less than 5% body weight (Figure 14a); all the H9N2att vaccinated 
ferrets survived challenge (Figure 14b). However, they lost as much as 10% of their 
body weight (Figure 14a). In contrast, the H7N2att vaccinated ferrets were partially 
protected from challenge and lost up to 15% of their body weight (Figure 14a).  Only 
50% of these animals survived (Figure 14b). The challenge virus replicated to high 
titers in the nasal washes of all ferrets on days 1 and 3-post challenge (Figure 15). By 
day 5 post challenge, ΔH5N1att vaccinated ferrets were able to clear the challenge 
virus while the surviving H7N2att and H9N2att vaccinated ferrets were able to 
reduce challenge virus titers by 5 dpc and completely clear it by 7 dpc (Figure 15). 
These results suggest that our WF10att backbone is protective in multiple species 




H7N2att vaccinated Balb/c mice were completely protected from HPAI H5N1 while 








Figure 14. Percent body weight and survival of vaccinated ferrets challenged 
with A/Vietnam/1203/2004 (HPAI H5N1). Ferrets were challenged i.n. with lethal 
dose of 2 x 105 PFU of HPAI H5N1. Body weights were recorded and clinical signs 
were observed for 14 dpc. (A) Body weight loss. The ΔH5N1att immunized ferrets 
lost less than 5% of their body weight and displayed no disease signs. The H9N2att 
immunized ferrets lost 10% of their body weight and displayed a range of disease 
signs from mild to moderate. The H7N2att immunized ferrets lost 15% of their body 
weight and displayed moderate disease signs. (B) Percent survival. All of the 
ΔH5N1att and H9N2att vaccinated ferrets survived challenge, while only 50% of the 
H7N2att vaccinated ferrets survived challenge. Data represents three independent 
experiments. Mild clinical signs include decreased activity (animals are alert but 
playful only when stimulated), nasal rattling, less than 5% body weight loss, or no 
increase in body temperature. Moderate clinical signs include decreased activity (alert 
but not playful), nasal discharge, sneezing, ocular discharge, diarrhea, inappetence, 
≥10% body weight loss, or an increase in body temperature no more than 2°. Severe 
clinical signs include no activity (animals are neither alert or playful when 
stimulated), mouth breathing, labored breathing, wheezing, inappetence, ≥15% body 





Figure 15. Clearance of A/Vietnam/1203/2004 (HPAI H5N1) challenge virus in 
ferrets immunized with recombinant vaccines. Vaccinated ferrets were challenge 
with 2 x 105 PFU of HPAI H5N1. On days 1, 3, 5, and 7 post-challenge, nasal washes 
were collected and challenge virus was titered by TCID50. The challenge virus was 
detected in the nasal washes of both the control ferrets and the vaccinated ferrets. 
ΔH5N1att vaccinated ferrets cleared the virus by day 5 post challenge. Both the 
H7N2att and H9N2att vaccinated ferrets cleared the challenge virus by day 7 post-
challenge. The challenge virus titers remained high in the control ferrets. Data 
combined from three independent experiments. Data are mean ± SE of nasal washes 
(log10 TCID50/mL) for 6 ferrets per group. 

















Recent studies have indicated that transferring the ts amino acid signature of 
the master donor strain A/Ann Arbor/6/60 (H2N2) (MDV-A) into different human 
influenza strains results in a ts phenotype in vitro and attenuation in ferrets (Jin, Zhou 
et al. 2004). Due to the transferable nature of the ts mutations of the MDV-A virus, 
we sought to determine whether such mutations would impart a similar phenotype to 
an AIV in mammals. For this purpose, we chose a virus that has demonstrated a broad 
host range in order to generate an attenuated virus backbone that could be used for the 
development of a universal vaccine for multiple animal species (i.e. from poultry to 
humans). We chose the internal genes of the AIV A/guinea fowl/Hong 
Kong/WF10/99 (H9N2), which replicates and transmits efficiently in birds, causes 
respiratory disease in mice without adaptation and replicates efficiently in ferrets 
(Choi, Ozaki et al. 2004; Wan, Sorrell et al. 2008; Sorrell, Wan et al. 2009). We 
successfully generated attenuated H1N1, H5N1, H7N2, and H9N2 reassortant viruses 
with the internal genes from the WF10att virus backbone. Previously, we showed the 
WF10att backbone was able to replicate in the upper respiratory tract of chickens and 
very little virus was found in the lungs or cloaca, suggesting attenuation in chickens 
(Song, Nieto et al. 2007). In these current studies, we have shown that the WF10att 
backbone is also attenuated in both mice and ferrets (Figure 2, 3, 13 and Tables 3 and 
4). In addition to being attenuated, the vaccines were protective against homotypic 
challenge with an H1N1 or HPAI H5N1 challenge in both animal models (Figures 5, 




depending on the surface proteins expressed and the challenge viruses used. In the 
mouse model, both H7N2att and H9N2att vaccinated mice were protected against 
H1N1 challenge with either an old (Figure 5) or contemporary virus (Figure 6). 
Surprisingly in both mice and ferrets, during HPAI H5N1 challenge, we found a 
difference in Het-I depending on the surface glycoproteins expressed in our vaccine. 
The H7N2att vaccine was protective in mice (Figure 7) and the H9N2att vaccine was 
protective in ferrets (Figure 14) against HPAI H5N1 challenge. In the mouse model, 
two doses of H9N2att vaccine was needed for protection against HPAI H5N1 
challenge (Figure 11). Given our observed differences, it will be interesting to 
determine the mechanisms involved in inducing Het-I in these two models especially 
since influenza infection in ferrets more closely resembles human influenza infection. 
In addition, the genetic variability in ferrets is also reflective of the human 
population. 
With the declaration of the first pandemic in over forty years in 2009, the 
swine-origin H1N1 pandemic highlights the need for influenza vaccines that induce 
broader protection against all subtypes of influenza. Few studies have focused on the 
ability of live attenuated influenza vaccines to induce Het-I in both the ferret and 
mouse models, and even fewer studies have examined the ability of various influenza 
surface glycoproteins to induce Het-I outside of the H1 and H3 subtypes.  To study 
the mechanisms of Het-I, predominately two virus strains are used in the literature, 
A/Puerto Rico/8/1934 (H1N1) (PR8) and A/Hong Kong/X31/1968 (H3N2) (X31). 
X31 is a reassortant virus containing the internal genes from PR8 and H3N2 surface 




the information observed in the literature correlates with other subtypes of influenza. 
Our study is unique because it focuses on the induction of Het-I by a live attenuated 
avian backbone. Here we show a live attenuated avian backbone expressing different 
surface glycoproteins differentially induces Het-I in the mouse and ferret models. 
Furthermore, we developed a model system to study the mechanism of Het-I because 
we have a vaccine that induces Het-I and another vaccine that does not.  It will be 
interesting to uncover the immune response generated by our WF10att backbone 
expressing different surface glycoproteins in both mice and ferrets. The only 
recombinant vaccine that replicated in the mouse lung was H7N2att (Table 2), which 
is the vaccine that induced Het-I in HPAI H5N1 challenge (Figure 7). It is possible 
that replication alone may be responsible for the induction of Het-I at least in mice. 
The picture in ferrets is less clear; Both the H7N2att and H9N2att vaccines replicated 
in the nasal turbinates, however none of our vaccines replicated in the lungs of ferrets. 
Therefore, it is likely that factors other than pulmonary replication are involved in the 
induction of Het-I.  
Previous studies have indicated a role for T cells specific to conserved regions 
of the virus in Het-I (Furuya, Chan et al.; Benton, Misplon et al. 2001; Alsharifi, 
Furuya et al. 2009). We plan to determine the quality of the immune response 
generated post vaccination using T cell ELISPOTs. Any differences in the quality of 
immune response between the vaccines would depend on the surface proteins or the 
compatibility of the surface proteins with the internal WF10att genes. In addition, 
others have found a role for B cells in Het-I (Nguyen, van Ginkel et al. 2001; 




2008; Quan, Compans et al. 2008). We also plan to perform microneutralization and 
ELISA assays on the immune sera collected from the vaccinated mice and ferrets to 
see if any cross-reactive neutralizing or non-neutralizing antibodies are present, and 
lastly we plan to perform vaccination and challenge studies in JhD-/- mice, which lack 
antibodies, to determine the role of antibodies in Het-I observed with our WF10att 
backbone. 
There are obvious limitations in the preparation of influenza vaccine stocks 
for a pandemic due to the rapid mutability of the virus. Thus, it is not possible to 
predict whether the antigenic make-up of the vaccine seed stock would confer 
protective immunity against the pandemic strain. Therefore, it would be advantageous 
for the vaccine seed stocks to protect against many subtypes of influenza. 
Understanding the mechanisms of Het-I will allow the development of vaccines that 





Table 10. Summary survival table of all challenge studies performed. 
 
  Challenge Virus 
Strain Vaccine WSN H1N1 pH1N1 HPAI H5N1 
Balb/c mice WSN H1N1att +++   
 pH1N1att  +++  
 ΔH5N1att   +++ 
 H7N2att +++ +++ +++ 
 H9N2att +++ +++ -- 
C57BL/6 mice ΔH5N1att   ++ 
 H7N2att   + 
 H9N2att   + 
Ferrets ΔH5N1att   +++ 
 H7N2att   ++ 
 H9N2att   +++ 
 
+++, 100% survival  
++, 50% survival 
+, <50% survival 
--, 0% survival 




Chapter 4: Mechanisms of heterosubtypic immunity 
induced by a modified live attenuated avian influenza A 
backbone 
4.1 Abstract 
 Current seasonal influenza vaccines are unable to protect against antigenically 
distinct viruses; therefore, it is extremely important to understand the mechanisms 
involved in the induction of heterosubtypic immunity (Het-I), the ability of one 
subtype to protect against a different subtype. We developed a modified live 
attenuated avian influenza A backbone using the virus strain A/guinea fowl/Hong 
Kong/WF10/1999 (H9N2) (WF10) and transferring the temperature sensitive (ts), 
cold-adapted (ca), and attenuated (att) mutations into this virus. In addition, a HA tag 
was placed in-frame at the C-terminus of the PB1 gene. This recombinant virus is 
designated WF10att. We found that our WF10att backbone expressing H7N2 surface 
glycoproteins was protective in Balb/c mice against A/Vietnam/1203/2004 (HPAI 
H5N1) challenge. We were interested in determining the mechanisms involved in the 
Het-I.  We found no role for IFN-γ, IL-1β, and TNF-α induction post vaccination or 
cross-reactive neutralizing antibodies in the induction of Het-I. However, we found 
that B cells are involved in Het-I. Cross-reactive non-neutralizing antibodies to non-
hemagglutinin viral proteins were detected. In addition, naïve Balb/c mice were 
passively transferred by intraperitoneal injection with sera collected at 21 days post 
vaccination (dpv) from vaccinated Balb/c mice. Three out of ten mice that received 




mice receiving H7N2att sera were protected from challenge with HPAI H5N1. These 
results were confirmed using JhD-/- mice, which lack mature B-lymphocytes. JhD-/- 
mice vaccinated with the recombinant vaccines and challenged with HPAI H5N1 did 
not survive challenge further suggesting a potential role for B cells in Het-I. Also 
cells isolated from the lungs of H7N2att vaccinated mice had antibody-secreting cells 
targeted to HPAI H5N1. Together these results further suggest a role for B cells in the 
induction of Het-I with our WF10att backbone. Although B cells are important, our 
results suggest a role for other immune cells in Het-I. Both IFN-γ and Granzyme B 
secreting cells were detected in lung and spleen cells isolated from H7N2att 
vaccinated mice and stimulated with HPAI H5N1. Our modified live attenuated avian 
influenza A backbone uses multiple immune cell populations to induce Het-I. 
4.2 Introduction 
4.2.1 Proposed mechanisms of heterosubtypic immunity 
 Heterosubtypic immunity (Het-I) is the ability of one subtype of influenza to 
protect against a different subtype of influenza.  Current seasonal vaccines are unable 
to induce Het-I and protect against antigenically distinct viruses; this was recently 
demonstrated by the novel H1N1 pandemic (pH1N1) in 2009. A monovalent vaccine 
containing the pH1N1 was prepared and available later in the influenza season. It is 
crucial that researchers elucidate the mechanism of Het-I so that seasonal vaccines 
can protect against subtypes not contained in the vaccine.  This may decrease the 
severity of a pandemic; Het-I does not prevent infection however viral titers and lung 
pathology are reduced allowing recovery from the disease.  This may save lives and 




mechanisms of Het-I have been analyzed for >40 years (Schulman and Kilbourne 
1965). Many researchers observed a substantial role for T cells in Het-I. It is thought 
T cells directed to the internal genes of influenza, specifically the NP and M genes, 
mediate Het-I because these genes are the most conserved between different subtypes 
of influenza A virus.  
Perrone and colleagues immunized mice with virus like particles (VLPs) 
containing the HA, NA, and M genes from the 1918 Spanish flu and observed 
protection against HPAI H5N1. No neutralizing antibodies were detected suggesting 
a role for T cell in this Het-I (Perrone, Ahmad et al. 2009). Similar results were 
observed when mice were primed with a live H3N2 virus and challenged with HPAI 
H5N1. Cross-reactive CD8+ T cells to the HPAI H5N1 were detected in splenocytes 
isolated from mice primed with H3N2 virus (Kreijtz, Bodewes et al. 2009). In 
addition, splenic transfer experiments in mice demonstrated that CD8+ T cells were 
responsible for heterosubtypic protection (Grebe, Yewdell et al. 2008). Also Benton, 
et al used knockout mice and found antibodies (IgA-/-, Ig-/-) and natural killer T cells 
(NKT) are not necessary for Het-I; however, both CD8+ and CD4+ T cells were 
important in the induction of Het-I (Benton, Misplon et al. 2001).  
In contrast, antibodies to the surface glycoproteins, HA and NA, are extremely 
important in homotypic immunity; however, it is thought that antibodies to HA and 
NA have no role in Het-I. Some researchers have found a prominent role for HA- and 
NA-specific antibodies in Het-I. Quan and colleagues found an increase in heat stable 
components (most likely neutralizing antibodies) occurred in mice when immunized 




CD4+ T cells were immunized with the same vaccine and adjuvant were also 
protected from heterosubtypic challenge (Quan, Compans et al. 2008) suggesting B 
and not T cells are important for protection against heterosubtypic challenge. Nguyen, 
et al also found antibodies played a role in Het-I when they used TdT-/- (B cells are 
less polyreactive and T cells are more promiscuous) and ΔD-iD (impaired B cell 
development and antibody production) knockout mice.  The majority of these mice 
did not survive heterosubtypic challenge although they had similar cytotoxic T cell 
activity as wildtype mice (Nguyen, Zemlin et al. 2007) suggesting humoral immunity 
is needed for protection against heterosubtypic challenge. 
There are studies that suggest multiple immune cells are involved in Het-I. 
Epstein, et al explored the roles of different T cell subsets and antibodies in Het-I 
using knockout mice primed with live virus of one subtype and challenged with 
another subtype. They found that a lack of CD8+ or CD4+ T cells alone had no effect 
on mice surviving Het-I challenge. Passive transfer experiments using the serum from 
primed mice found that naïve mice that received the serum did not survive challenge 
suggesting that antibodies have no role in Het-I. In addition mice lacking transported 
IgA were protected from heterosubtypic challenge suggesting no role for transported 
IgA (Epstein, Lo et al. 1997). These results implicate a role for redundancy in the 
immune system.  Other immune cell populations present can compensate for the lack 
of one or more cell subsets. Other researchers observed mice deficient in γδ T cells in 
addition to CD4+ and CD8+ T cells were not protected against heterosubtypic 
challenge (Benton, Misplon et al. 2001; Grebe, Yewdell et al. 2008). Therefore, it is 




for Het-I. A better understanding of the specific immune cells involved in the 
induction of Het-I by influenza vaccines, both inactivated and live attenuated, is 
important in the development of improved vaccines that are able to protect against 
multiple influenza subtypes and possibly protect against a pandemic influenza strain. 
4.3 Methods and materials 
4.3.1 Microneutralization Assay 
 Blood was collected from specific pathogen free (SPF) Balb/c mice (NCI, 
Fredrick, MD) at 21 days post vaccination (dpv) from the submandibular vein; blood 
was collected from ferrets at 7, 14, and 21 dpv from the vena cava. The blood was 
allowed to clot overnight at 4°C. To collect the sera, the blood was centrifuged at 
2,000 rpm for 5 minutes. The serum was removed, aliquoted into new tubes, and 
stored at -20°C until processed. All sera were diluted 1:3 with receptor-destroying 
enzyme (RDE) from Vibrio cholerae (Fisher Scientific, Pittsburgh, PA) and incubated 
at 37°C overnight to destroy nonspecific serum inhibitor activity. The next day, the 
sera were transferred to a 56°C water bath and incubated for 45 min to inactivate the 
RDE. Then the sera were diluted 1:10 and 0.1 mL were placed in the first row of a 
96-well flat-bottom plate. The sera were serially diluted two-fold in PBS within the 
96-well flat-bottomed plate (50µl per well). Following the addition of 50µl containing 
100 TCID50 of virus diluted in PBS into each well, the plates were mixed and 
incubated at 37°C for 1 h. Subsequently, the serum:virus mixture (0.1 mL) was added 
to a monolayer of MDCK cells in a 96-well plate. The plate was incubated at 4°C for 
15 min and then transferred to 37°C for 45 min. After incubation, the serum:virus 




California) with 1µg TPCK-trypsin/mL (Sigma, St. Louis, MO) was added. The cells 
were incubated at 37°C for 3 days and an HA assay was performed on the 
supernatant. Neutralizing antibody titers were expressed as the reciprocal of the 
highest dilution of the sample that completely inhibited hemagglutination. HA assays 
were performed following the recommendations of WHO/OIE (WHO 2011). 
4.3.2 ELISA 
 Serum from immunized Balb/c mice (NCI, Fredrick, MD) collected at 4, 7, 
14, and 21 dpv were tested by ELISA for the presence of antiviral immunoglobulins. 
The sera was pooled from four individual mice.  All sera were diluted 1:3 with RDE 
and incubated at 37°C overnight to destroy nonspecific serum inhibitor activity. Nunc 
immuno plates (Thermo Scientific, Rochester, NY) were coated with 1000 HA units 
(HAU) of β-Propiolactone (βPL)-inactivated A/Vietnam/1203/2004 (ΔH5N1) virus  
or 1.0µg of H5 protein from A/Vietnam/1203/2004 (HPAI H5N1) virus (Protein 
Sciences Corporation, Meriden, CT) per well in 100µl bicarbonate carbonate coating 
buffer. The ΔH5N1 virus has the polybasic cleavage site removed from the HA 
protein so that the virus is no longer a HPAI virus and can be used at BSL-2 levels. 
Control wells received either allantoic fluid or FLAG peptide (Sigma, St. Louis, MO). 
The ELISA plate was incubated at 4°C overnight. The next day, the sera were 
transferred to a 56°C water bath and incubated for 45 min to inactivate the RDE. 
Prior to adding the sera diluted 1:20 to the plate, the plate was blocked with 5% Non-
fat milk (BioRad, Hercules, CA) for 1 h. The diluted sera samples were added to the 
plate and incubated at 37°C for 2 h. After the incubation, the plate was washed three 




horseradish peroxidase (1:5000) (SouthernBiotech, Birmingham, AL) was added to 
the plate and incubated at room temperature for 1 h. Excess antibody was washed 
away using PBS-T. The last wash was PBS and then 0.1 mL of a 1:1 mixture of TMB 
Peroxidase substrate and Peroxidase substrate solution B (KPL, Gaithersburg, MD) 
was added to each well. The reaction was stopped after two minutes with TMB Blue 
stop solution (KPL, Gaithersburg, MD). The plate was read on a plate reader at 630 
nm.  
4.3.3 Passive transfer of sera from vaccinated Balb/c mice 
 To determine the role of B cells in heterosubtypic immunity (Het-I), five-
week-old female specific pathogen free (SPF) Balb/c mice (10 per group) were 
passively immunized by intraperitoneal (i.p.) injection with 100µl of sera from 
ΔH5N1att, H7N2att, or H9N2att immunized mice collected at 21 dpv. Control 
animals received injections of day 0 pre-vaccinated sera. There was a total of 3 i.p. 
injections of sera administered 24 h apart, 3 days before challenge. Twenty-four hours 
after the third injection, mice were administered isofluorane using Vetequip mobile 
anesthesia system (Vetequip, Inc, Pleasanton, CA) and challenged intranasally (i.n.) 
with 5 MLD50 of HPAI H5N1. The body weights and disease signs of the mice were 
monitored and recorded daily for 21 dpc. HPAI H5N1 challenge was performed 
under BSL-3+ conditions with USDA approval and according to protocols approved 
by the Institutional Animal Care and Use Committee of the University of Maryland, 
College Park. 
4.3.4 Immunization and challenge of JhD-/- mice. 




SPF JhD-/- mice (Taconic Farms, Inc, Hudson, NY) were anesthetized with 
isofluorane administered using Vetequip mobile anesthesia system (Vetequip, Inc, 
Pleasanton, CA) before i.n immunization. Mice were immunized i.n. with 106 EID50 
of the recombinant vaccines in 50µl PBS; all mock-immunized mice received 50µl 
PBS.  The 50 % mouse lethal dose (MLD50) for the challenge virus, HPAI H5N1, was 
calculated using groups of four mice inoculated i.n. with various doses ranging from 
100 to 105 EID50, and the Reed and Muench method was used to calculate the MLD50 
(Reed 1938). Clinical signs, body weight and mortality of mice were monitored and 
recorded for 21 dpv. At 21 dpv, the immunized mice were challenged with 20 MLD50 
of HPAI H5N1 virus i.n. in 50µl PBS. Clinical signs, body weight and mortality of 
mice were monitored and recorded for 21 dpc. HPAI H5N1 challenge was performed 
under BSL-3+ conditions with USDA approval and according to protocols approved 
by the Institutional Animal Care and Use Committee of the University of Maryland, 
College Park. 
4.3.5 Spleen and lung cell isolation from mice 
Total cells were isolated from the spleen and lungs of immunized female 
Balb/c mice. Five-week-old female SPF Balb/c mice (NCI, Fredrick, MD) were 
anesthetized and immunized as described above.   At 7, 14, or 21 dpv, mice were 
bled, anesthetized, and sacrificed by cervical dislocation. Spleens and lungs were 
removed aseptically and placed in separate 70-µM cell strainers over 50 mL tubes. 
The organs were completely mashed using a syringe plunger; ten milliliters of 
complete RPMI were used to wash the cell strainer and wash through all the cells.   




(Fisher scientific, Pittsburgh, PA) to lyse the red blood cells. The cells were 
resuspended in complete RPMI media and used for subsequent assays. 
4.3.6 B cell ELISPOT 
ELISPOT plate (Millipore, Billerica, MA) was pre-wet with 35% ethanol and 
washed three times with PBS. Then the plate was coated with 30,000 HAU per mL of 
βPL-inactivated ΔH5N1 virus (50µl per well) and incubated overnight at 4°C. Prior to 
seeding the wells, the plate was blocked with complete RPMI media for 2 h at room 
temperature. Cells from the spleen and lungs of  vaccinated Balb/c mice were isolated 
at 7, 14, and 21 dpv. Lung cells were added at a concentration of 3.0 x 105 cells per 
well and 3.0 x 106 per well for spleen cells. To determine the background level of 
spots, wells with no cells added were included. Cells were incubated overnight (~20 
h) at 37°C. Wells were washed with PBS containing Tween-20 (PBS-T) and mouse 
antibodies were probed using goat anti-mouse IgG conjugated to biotin (1:1500) 
(Sigma, St. Louis, MO) and incubating overnight at 4°C. After washing with PBS-T, 
horseradish peroxidase strepavidin (1:2000) (Vector Laboratories, Burlingame, CA) 
was added and incubated at room temperature for 2 h. After incubation, the plate was 
washed with PBS-T and then PBS. AEC substrate (BD Biosciences, San Jose, CA) 
was added to develop the spots. Plates were sent to Zellnet Consulting, Inc (Fort Lee, 
NJ) to count the spots per well.  
4.3.7 Cytokine profile of vaccinated Balb/c mice 
 To determine whether there is a difference in the cytokine profile induced by 
the recombinant vaccines, the levels of IFN-γ, IL-1β, and TNF-α post vaccination was 




i.n. with 106 EID50 of ΔH5N1att, H7N2att, or H9N2att in 50µl PBS; all mock 
immunized control mice received 50µl PBS. At three and five days post vaccination, 
mice were bled, anesthetized, and sacrificed by cervical dislocation. Lungs were 
collected and homogenized. Homogenates were clarified by centrifugation and stored 
at -80°C until they were shipped to the University of Maryland Cytokine Core 
Laboratory (Baltimore, MD) where a Luminex 100 system was used to determine the 
levels of IFN-γ, IL-1β, and TNF-α cytokines.   
4.3.8 IFN-γ ELISPOT 
 To determine the level of IFN-γ secreting cells post vaccination, an ELISPOT 
plate (Millipore, Billerica, MA) was pre-wet with 35% ethanol and washed three 
times with PBS. The plate was then coated with anti-mouse IFN-γ (1:200) (BD 
Biosciences, San Jose, CA) and incubated overnight at 4°C. The plate was blocked 
with complete RPMI media after washing with PBS and incubated at room 
temperature for 2 h. Cells from the spleen and lungs of immunized Balb/c mice were 
isolated at 7 and 21 dpv. Lung cells were added to each well at a concentration of 3.0 
x 105 cells and 3.0 x 106 cells per well for spleen cells. βPL-inactivated virus was 
added to the cells for stimulation.  To determine the background spot levels, media 
alone was added to cells and wells containing no cells were added for negative 
controls. Cells plus virus stimulant were incubated at 37°C for ~20 h. The next day 
wells were washed with PBS-T and anti-mouse IFN-γ conjugated to biotin (1:2000) 
(BD Biosciences, San Jose, CA) was added and incubated overnight at 4°C. After 
incubation, the plate was washed with PBS-T and then horseradish peroxidase 




at room temperature. After washing with PBS-T, AEC substrate (BD Biosciences, 
San Jose, CA) was added to visualize the spots. Plates were sent to Zellnet 
Consulting, Inc (Fort Lee, NJ) to count the spots per well.  
4.3.9 Granzyme B ELISPOT 
ELISPOT plate (Millipore, Billerica, MA) was pre-wet with 35% ethanol and 
washed three times with PBS. The plate was then coated with 1µg of anti-mouse 
Granzyme B purified antibody (eBiosciences, San Diego, CA). The plate was 
incubated overnight at 4°C. The next day the plate was blocked with complete RPMI 
media after one wash with PBS and incubated at room temperature for 2 h. Cells from 
the spleen and lungs of immunized Balb/c mice were isolated at 14 and 21 dpv. Lung 
cells were added to each well at a concentration of 3.0 x 105 cells and 3.0 x 106 per 
well for spleen cells. Concanavalin A (ConA) (Sigma, St. Louis, MO) was added to 
the cells for stimulation.  To determine background levels, media alone was added to 
cells and wells containing no cells were included as negative controls. Cells plus 
stimulant were incubated at 37°C for 20 h. The next day wells were washed with 
PBS-T and anti-mouse Granzyme B conjugated to biotin (1:2000) (BD Biosciences, 
San Jose, CA) was added to each well. The plate was incubated overnight at 4°C. 
After incubation, the plate was washed with PBS-T and then horseradish peroxidase 
strepavidin (1:2000) (Vector Laboratories, Burlingame, CA) was added and incubated 
for 2 h at room temperature. After washing with PBS-T and PBS alone, AEC 
substrate (BD Biosciences, San Jose, CA) was added to visualize the spots. Plates 





4.4.1 Variations in the ability of recombinant WF10att viruses to induce 
neutralizing antibodies in Balb/c mice 
 To determine whether neutralizing antibodies play a role in protection from 
heterosubtypic challenge, we performed microneutralization assays using vaccinated 
mouse sera.  Mice were vaccinated i.n. with the recombinant vaccines. A 
microneutralization assay was performed using the homologous vaccine as well as the 
challenge virus to see if any cross-reactive antibodies were detected in sera pooled 
from four individual mice. Although H7N2att vaccinated Balb/c mice were protected 
from challenge with HPAI H5N1, we were unable to detect cross-reactive 
neutralizing antibodies to WSN and HPAI H5N1, which suggests that the Het-I 
induced by our WF10att backbone is independent of neutralizing antibodies (Table 
11). Neutralizing antibodies to the homologous virus were detected in all the 
vaccinated mice except ΔH5N1att vaccinated mice where no homologous 
neutralizing antibodies were detected at 21 dpv (Table 11). However, the ΔH5N1att 

















Table 11. Microneutralization (MN) antibody titers in Balb/c sera against 
homologous and heterologous viruses 















PBS Control - <10 <10 <10 
WSN H1N1att 106 160 160 <10 
∆H5N1att 106 <10 <10 <10 
H9N2att 106 10 <10 <10 
H7N2att 106 40 <10 <10 
  






4.4.2 Variations in the ability of recombinant WF10att viruses to induce 
neutralizing antibodies in ferrets 
To determine whether neutralizing antibodies play a role in protection from 
heterosubtypic challenge, we performed microneutralization assays on the vaccinated 
ferret sera.  Ferrets were vaccinated i.n. with 106 EID50 or TCID50 of ΔH5N1att, 
H7N2att, or H9N2att in 0.5 mL PBS; control ferrets received 0.5 mL PBS. At 7, 14 
and 21 dpv, ferrets were bled from the vena cava, and sera were collected.  A 
microneutralization assay was performed using the homologous virus as well as the 
challenge virus to see if any cross-reactive neutralizing antibodies were detected. 
Although the H9N2att vaccinated ferrets were completely protected from challenge 
with HPAI H5N1, we were unable to detect cross-reactive antibodies to the challenge 
virus HPAI H5N1, which suggests that neutralizing antibodies are not involved in 
Het-I (Table 12). Neutralizing antibodies to the homologous virus were detected in all 
the vaccinated ferrets except ΔH5N1att vaccinated ferrets where no neutralizing 
antibodies were detected post vaccination (Table 12). However, 100% of these ferrets 




Table 12. Microneutralization (MN) antibody titers in ferret sera pre-challenge 















PBS Control - 21 <10 <10 
∆H5N1att 106 7 <10 <10 
  14 <10 <10 
  21 <10 <10 
H7N2att 106 7 160, 160, 10, 10, 20, 10 
<10 
  14 320, 320, 160, 40, 320,160 
<10 
  21 640, 160, 160, 320, 320, 160 
<10 
H9N2att 106 7 >1280, 320, 160, 320, 80, 80 
<10 












<10, indicates undetectable levels of antibodies 





4.4.3 Determining the role of non-neutralizing antibodies in Het-I induced by the 
WF10att backbone in Balb/c mice. 
 Because no cross-reactive neutralizing antibodies to the heterosubtypic 
challenge virus were detected in the sera of immunized mice, we sought to determine 
the role of non-neutralizing antibodies in Het-I.  An ELISA assay was performed 
using the sera from PBS, ΔH5N1att, H7N2att, or H9N2att immunized mice (n=4). 
The first ELISA was coated with a recombinant A/Vietnam/1203/2004 H5 protein. 
ΔH5N1att sera collected at 14 and 21 dpv were positive for antibodies directed to the 
H5 protein (Figure 16a). H9N2att sera collected at 21 dpv had a small amount of 
antibodies that cross-reacted with the H5 protein; however, H7N2att sera had similar 
levels to the PBS control group indicating no cross-reactive antibodies were present 
to the H5 protein although 100% of these animals were protected from HPAI H5N1 
(Figure 16a). Next we examined the presence of cross-reactive antibodies to other 
viral proteins. An ELISA plate was coated with βPL-inactivated ΔH5N1 virus, and 
sera from mice immunized with the recombinant vaccines were added. Similar to the 
H5 protein ELISA, ΔH5N1att had the highest levels of non-neutralizing antibodies to 
the ΔH5N1 virus at 14 and 21 dpv (Figure 16b).  Both H7N2att and H9N2att had 
similar low levels of cross-reactive non-neutralizing antibodies at 14 and 21 dpv to 
ΔH5N1 viral proteins suggesting a potential role for non-neutralizing antibodies to 







Figure 16. Serum antibody response to H5 HA protein from 
A/Vietnam/1203/2004 (HPAI H5N1) virus or βPL-inactivated ΔH5N1 virus after 
vaccination with recombinant vaccines. Sera samples from immunized Balb/c mice 
were tested in an ELISA to determine the level of non-neutralizing HA specific 
proteins and non-HA specific proteins to HPAI H5N1 virus. (A) ELISA plate coated 
with H5 recombinant protein. At days 4 and 7 post vaccination, no non-neutralizing 
antibodies were detected in any of the four groups. At days 14 and 21 dpv, the 
ΔH5N1att sera had high levels of antibodies to the H5 protein. At 21 dpv, H9N2att 
sera had a small level of cross-reactive non-neutralizing antibodies to the H5 protein; 
however, H7N2att sera had no cross-reactive non-neutralizing antibodies to the H5 
protein at 4, 7, 14, or 21 dpv. (B) ELISA plate coated with βPL-inactivated ΔH5N1 
virus. At days 4 and 7 post vaccination, no non-neutralizing antibodies were detected 
in any of the four groups. At days 14 and 21 dpv, the ΔH5N1att sera had high levels 
of antibodies to the ΔH5N1 virus. At 14 and 21 dpv, H7N2att and H9N2att sera had a 
small level of cross-reactive non-neutralizing antibodies to the ΔH5N1 virus. Data are 
mean ± standard deviation (SD) of OD values for 4 individual mouse serum pooled 




4.4.4 Determining the role of B cells in Het-I induced by the WF10att backbone 
in Balb/c mice. 
After detecting cross-reactive non-neutralizing antibodies to HPAI H5N1 in 
the sera of heterosubtypically vaccinated mice, we wanted to further determine the 
role for B cells in Het-I.  Five-week-old naïve female Balb/c mice were passively 
immunized by intraperitoneal (i.p.) injection with 100µl of sera from ΔH5N1att, 
H7N2att, or H9N2att immunized mice collected at 21 dpv. Naïve mice received pre-
immune sera collected at day 0. All mice received a total of three i.p. injections of 
100µl of sera 24 h apart prior to challenge. Twenty-four hours after the third 
injection, mice were challenged with 5 MLD50 of HPAI H5N1. Mice were monitored 
daily for clinical signs of disease including body weight, grooming, activity, and 
respiratory signs. Control mice that received sera from unimmunized mice started 
losing weight at 6 dpc and displayed a rough coat, hunched posture, inactivity, and 
respiratory signs until most mice died by 10 dpc and the last mouse died at 15 dpc 
(Figure 17a). The mice that received ΔH5N1att sera started losing body weight at 6 
dpc and a lack of grooming was evident.  As days progressed, mice continued to lose 
weight and displayed rough coat, hunched posture, respiratory signs, and inactivity 
until they died at 11 dpc. However, 3 of the 10 mice regained their body weight by 11 
dpc and survived the challenge (Figure 17a, 17b).  Both groups of mice receiving 
H7N2att and H9N2att sera began losing weight at 6 dpc similar to the other two 
groups, and their condition deteriorated over time and most mice (9 out of 10) died by 
17 dpc. However, one out of 10 mice did survive challenge (Figure 17a, 17b), which 
could suggest a potential role for antibodies in both homotypic and heterosubtypic 







Figure 17. Percent body weight and survival of Balb/c mice passively immunized 
with sera and challenged with A/Vietnam/1203/2004 (HPAI H5N1). Naïve 5-
week-old female Balb/c mice were passively transferred interperitoneally (i.p.) with 
100µl sera from mice previously immunized with ΔH5N1att, H7N2att, or H9N2att 
collected at 21 dpv. Control mice received i.p. injection of 100µl from pre-immunize 
sera. Each mouse received 3 i.p. injections with 100µl of sera 24 hours apart prior to 
challenge. Twenty-four hours after the third i.p. injection, mice were challenged with 
5 MLD50 of HPAI H5N1. (A) Body weights. All groups of mice started losing weight 
at 6 dpc. Mice receiving the ΔH5N1att sera lost a little less than 20% of their body 
weight until 9 dpc then the surviving (3 mice out of 10 mice) animals started 
regaining weight and survived challenge. Mice receiving the H7N2att lost 
approximately 15% of their body weight until 9 dpc and then the surviving animal 
regained its body weight and survived challenge. Mice receiving the H9N2att sera 
lost a little more than 20% of their body weight until 11 dpc and the surviving animal 
regained its body weight and survived challenge. (B) Percent survival. Three of the 
ten mice receiving the ΔH5N1att sera survived the HPAI H5N1 challenge. With the 





The ELISA and passive transfer studies suggested a small role for antibodies 
in Het-I induced by our WF10att backbone, we sought to confirm this using B cell 
deficient mice.  JhD-/- mice, which carry a deletion of the endogenous murine J 
segments of the Ig heavy chain locus resulting in no mature B-lymphocytes in the 
spleen, bone marrow, lymph nodes, peripheral blood or peritoneum, were immunized 
with the different recombinant vaccines and challenged with 20 MLD50 HPAI H5N1. 
Five-week-old female JhD-/- mice (n=10) were i.n. inoculated with 106 EID50 of 
ΔH5N1att, H7N2att, or H9N2att in 50µl of PBS; control animals received 50µl of 
PBS. No decreases in body weight or clinical signs were observed in the mice post 
vaccination indicating that the recombinant viruses were attenuated in these 
immunodeficient mice (Figure 18a). Since the recombinant viruses were attenuated in 
these mice, the mice were challenged with 20 MLD50 of HPAI H5N1 and monitored 
daily for disease signs and survival. All immunized and control animals began losing 
weight at 3 dpc and clinical signs such as lack of grooming and decrease in activity 
were observed. As days progressed, all mice continued to lose weight and displayed 
more clinical signs of disease such as rough coat, hunched posture, inactivity, and 
respiratory signs (Figure 18b). Control mice and H9N2att immunized mice died by 8 
dpc while ΔH5N1att and H7N2att immunized mice died by 9 dpc (Figure 18c).  
These results further suggest a role for antibodies in both homotypic and 







Figure 18. Percent body weight and survival of JhD-/- mice immunized with 
recombinant vaccines and challenge with A/Vietnam/1203/2004 (HPAI H5N1). 
Five-week-old female JhD-/- mice were immunized with 106 EID50 of ΔH5N1att, 
H7N2att, or H9N2att in 50µl PBS. Control mice received 50µl PBS. (A) Post 
vaccination percent body weight. Mice were monitored daily for disease signs for 
14 dpv. ΔH5N1att immunized mice gained 10% more body weight post vaccination 
while the other three groups, PBS control, H7N2att, and H9N2att immunized mice, 
gained approximately 5% of their body weight, and no disease signs were detected 
post vaccination. (B) Post challenge percent body weight and (C) Percent survival. 
JhD-/- mice immunized with the recombinant vaccines were challenged twenty-one 
days post vaccination with 20 MLD50 of HPAI H5N1. All groups of mice started 
losing weight at 4 dpc, and a lack of grooming was observed. Control and H9N2att 
immunized JhD-/- mice continued to lose weight and displayed disease signs including 
rough coat, hunched posture, inactivity, and respiratory signs until all mice died by 8 
dpc. Both the ΔH5N1att and H7N2att immunized mice continued to lose weight and 
displayed the same disease signs as the other two groups until their death at 9 dpc. No 






Lungs are the major site of antibody-secreting cells (ASCs) following 
wildtype virus infection (Joo, He et al. 2008); therefore, we decided to determine the 
number of ASCs in both the lungs and spleens of mice immunized with the different 
recombinant vaccines using a B cell ELISPOT. It is possible that the frequency of 
ASCs post vaccination may play a role in Het-I immunity. B cell ELISPOT plates 
were coated with βPL-inactivated A/Vietnam/1203/2004 (ΔH5N1) virus. The number 
of ASCs from total cells from the lung or spleen was determined at 7, 14, and 21 dpv. 
At 14 dpv, cells from H7N2att immunized mice had approximately 87 ASCs per 3.0 
x 105 cells in the lungs while ΔH5N1att and H9N2att cells had 24 and 30 ASCs, 
respectively (Figure 19a).  At day 21 post vaccination, the number of ASCs in the 
lungs increased for cells isolated from both ΔH5N1att and H9N2att to 109 and 138 
ASCs, respectively (Figure 19a).  Cells isolated from H7N2att had 75 ASCs directed 
to the ΔH5N1 virus (Figure 19a). No ASCs from any of the cells isolated from 
immunized mice spleens were detected (Figure 19b) suggesting the recombinant 
vaccines induced a local response. The cross-reactive ASCs detected in the lungs 






Figure 19. The induction of antibody-secreting cells (ASCs) in the lungs and 
spleens of mice immunized with recombinant vaccines. Five mice per vaccine 
group were sacrificed at days 7, 14, and 21 post vaccination, and the number of 
antibody-secreting cells (ASCs) to βPL-inactivated A/Vietnam/1203/2004 (ΔH5N1) 
virus were determined in the (A) lungs and (B) spleens. At 14 and 21 dpv, the 
ΔH5N1att immunized group secreted antibodies to the ΔH5N1 virus. Both the 
heterosubtypic immunized groups, H7N2att and H9N2att, secreted antibodies to the 
ΔH5N1 virus. No antibody-secreting cells to the ΔH5N1 virus were detected in the 
spleens of the immunized mice. Data are mean ± SD of ASCs per 3.0 x 105 cells in 





4.4.5 Determining the role of cytokines in Het-I induced by the WF10att 
backbone 
 Previous results have shown a role for B cells in Het-I induced by our 
WF10att backbone. We sought to determine if our WF10att backbone expressing 
different surface glycoproteins induced different cytokine profiles post vaccination 
and if a difference in cytokine profile plays a role in Het-I.  H7N2att was detected in 
the lungs of immunized mice at 3 dpv; in contrast, ΔH5N1att and H9N2att did not 
replicate in the lungs. Therefore, we thought the ability of this vaccine to replicate in 
the lungs resulted in an increased immune response—evidenced by an increase in the 
secretion of proinflammatory cytokines. A difference in cytokine profile may 
contribute to the ability of the H7N2att immunized mice to survive HPAI H5N1 
challenge. Therefore, five-week-old female Balb/c mice were vaccinated with 106 
EID50 of the recombinant vaccines, and control animals received PBS only. At three 
and five days post vaccination, mice were sacrificed. Lungs were collected and 
homogenized in PBS. The homogenates were analyzed by the Luminex 100 system 
for three cytokines, IFN-γ, IL-1β, and TNF-α. No difference in the level of all three 
cytokines, IFN-γ, IL-1β, and TNF-α (Figure 20a, b, c) was found suggesting a 





Figure 20. Cytokine levels in lung homogenates of Balb/c mice immunized with 
recombinant vaccines. Five-week-old female Balb/c mice were immunized with the 
recombinant vaccines or PBS. At three and five days post vaccination, mice were 
bled, anesthetized with isofluorane, and sacrificed by cervical dislocation.  Lungs 
were collected and homogenized in PBS. The lung homogenates were analyzed for 
cytokines by the Luminex 100 system. (A) IFN-γ, (B) IL-1β, and (C) TNF-α. No 
difference in any three of the cytokines was observed at 3 or 5 dpv between the 
ΔH5N1att, H7N2att, or H9N2att immunized groups and the PBS controls.  Data are 
mean ± SD of cytokine concentrations (pg/mL) for 5 mice per group. IFN, interferon, 





4.4.6 Determining the role of T cells in Het-I induced by the WF10att backbone. 
 To this point, B cells seem to play a role in Het-I with our WF10att backbone 
in mice. The question remains whether T cells play a role in Het-I; therefore, we 
isolated cells from Balb/c mice immunized with the three recombinant vaccines, 
ΔH5N1att, H7N2att, or H9N2att; control animals received PBS. We used an 
ELISPOT coated with an IFN-γ capture antibody to determine the frequency of IFN-γ 
secreting cells isolated from both lung and spleen and stimulated with ΔH5N1 virus. 
At both 7 and 21 dpv, all three vaccine groups had cells that secreted IFN-γ in the 
lungs (Figure 21a).  At 7 dpv, spleen cells from H7N2att immunized mice had 
detectable levels of IFN-γ secreting cells. However, at 21 dpv both cells isolated from 
ΔH5N1att and H7N2att had a larger number of IFN-γ secreting cells compared to 






Figure 21. IFN-γ production from lung and spleen cells in response to 
immunization with recombinant vaccines in Balb/c mice. (A) Lung and (B) 
Spleen cells were isolated from Balb/c mice immunized with the recombinant 
vaccines, ΔH5N1att, H7N2att, or H9N2att, at 7 and 21 dpv. The cells were added to 
ELISPOT plates coated with IFN-γ capture antibody and stimulated with 
A/Vietnam/1203/2004 (ΔH5N1) virus. At 7 and 21 dpv, lung cells isolated from all 
the immunized mice produced IFN-γ. At 7 dpv, the spleen cells isolated from 
H7N2att had cells secreting IFN-γ and by 21 dpv all vaccine groups had cells 
secreting a high amount of IFN-γ. Data are mean ± SD of spots per 3.0 x 105 cells 







 After analyzing the ability of the recombinant vaccines to induce IFN-γ 
secretion, we analyzed the ability of the recombinant vaccines to induced other 
immune cells that are able to lyse ΔH5N1 infected cells, which could play a role in 
Het-I. Therefore, we used an ELISPOT assay to determine the frequency of cells 
secreting Granzyme B. Granzyme B is a member of the granzyme family, which 
contains serine proteases found in cytotoxic granules secreted by cytotoxic T 
lymphocytes (CTL) and natural killer (NK) cells (Kam, Hudig et al. 2000; Smyth, 
Kelly et al. 2001). Granzyme B is able to access the target cell cytosol through holes 
made by perforin and induces cell death. Cells were isolated from both lungs and 
spleen. These cells were added to an ELISPOT plate coated with Granzyme B capture 
antibody and stimulated overnight with βPL-inactivated ΔH5N1 or ConA. We were 
unable to detect any Granzyme B secreting cells from the lungs when stimulated with 
either ΔH5N1 virus or ConA. Also no spots were detected from cells isolated from 
the spleen and stimulated with ΔH5N1 virus. However, higher levels of Granzyme B 
secreting cells were detected in spleen cells isolated from Balb/c mice immunized 
with ΔH5N1att and H7N2att when compared to H9N2att; these cells were stimulated 
with ConA (Figure 22). These Granzyme B secreting cells in the spleen may play a 
role in the ability of mice immunized with a single dose of H7N2att to be protected 





Figure 22. Induction of Granzyme B from spleen cells isolated from Balb/c mice 
immunized with recombinant vaccines. Spleen cells were isolated from Balb/c 
mice immunized with the recombinant vaccines, ΔH5N1att, H7N2att, or H9N2att; 
controls cells were isolated from mice immunized with PBS. The spleen cells were 
isolated at 14 and 21 dpv. The cells were added to an ELISPOT plate coated with 
Granzyme B capture antibody and stimulated with Concanavalin A (ConA). At 21 
dpv, higher levels of Granzyme B secreting cells were detected in spleen cells 
isolated from Balb/c mice immunized with ΔH5N1att and H7N2att when compared 
to H9N2att. Data are mean ± SD of spots per 3.0 x 106 cells from the spleen for 5 







This is the first time a live attenuated vaccine has shown a difference in Het-I 
depending on the surface glycoproteins expressed and the species vaccinated.  These 
findings suggest that Het-I is species specific and the ability of a vaccine to induce 
Het-I depends on the surface glycoproteins expressed by both the vaccine and 
challenge virus. We vaccinated mice with the same H7N2att and H9N2att vaccines 
and challenged them with either an H1N1 virus or HPAI H5N1. Both H7N2att and 
H9N2att vaccinated mice were protected from lethal challenge with 2 different H1N1 
strains. However, only H7N2att vaccinated mice were protected from HPAI H5N1. 
We suspected a role for the surface glycoproteins because our recombinant vaccines 
have the same attenuated internal genes from WF10att, or there was a difference in 
the interaction between the different surface glycoproteins and the internal genes. 
However, depending on the surface glycoproteins expressed on the vaccine and the 
challenge virus used, our WF10att backbone induces different levels of Het-I.  
We were unable to detect cross-reactive neutralizing antibodies to the HPAI 
H5N1 in the sera of H7N2att and H9N2att immunized mice or ferrets using a 
microneutralization assay (Hickman, Hossain et al. 2008) (Table 11 and 12). Previous 
research has observed the presence of Het-I in the absence of serum neutralizing 
antibodies (Perrone, Ahmad et al. 2009). Also in an ELISA, no cross-reactive non-
neutralizing antibodies to the HPAI H5 recombinant protein were detected in the 
H7N2att sera; however, cross-reactive non-neutralizing antibodies to the H5 protein 




influenza hemagglutinin proteins are separated into two groups based on their 
primary sequence. H1, H5 and H9 are in group 1 while H7 is in group 2. Therefore, 
cross-reactive non-neutralizing antibodies from H9N2att to H5 protein were 
expected. However, these non-neutralizing antibodies are not involved in protection 
because the H9N2att vaccinated mice did not survive protection from HPAI H5N1 
challenge. When we used an ELISA coated with βPL-inactivated ΔH5N1 virus, we 
were able to detect non-neutralizing antibodies to viral proteins other than HA in both 
H7N2att and H9N2att sera (Figure 16b) suggesting a potential role for non-
neutralizing antibodies to non-HA viral proteins in the protection of H7N2att 
vaccinated mice from HPAI H5N1 challenge. Tumpey, et al also detected non-
neutralizing antibodies in the sera and lung washes of mice immunized with an 
inactivated X-31 vaccine and found a role for B cells in protection against 
heterosubtypic challenge with HPAI H5N1 (Tumpey, Renshaw et al. 2001). Others 
have found a role for antibodies directed to the conserved internal proteins such as NP 
(Carragher, Kaminski et al. 2008) and M2 (Neirynck, Deroo et al. 1999; Fan, Liang et 
al. 2004; Tompkins, Zhao et al. 2007). However, in our system non-neutralizing 
antibodies cannot be the whole story because both heterosubtypic challenged mice 
(H7N2att and H9N2att) contained non-neutralizing antibodies to the challenge virus; 
however, only H7N2att mice were protected from challenge suggesting more immune 
mechanisms are involved. 
 We further examined the role of antibodies in Het-I induced by our WF10att 
backbone because previous studies have found a substantial role for B cells and not T 




Nguyen, Zemlin et al. 2007; Quan, Compans et al. 2008). However, most of these 
studies have focused on the ability of two subtypes, H1N1 and H3N2, to induce Het-
I. In addition, most studies have been performed with either live virus or inactivated 
vaccines. Therefore, there is a lack of information within the literature regarding the 
ability of live attenuated vaccines and different influenza subtypes, besides H1N1 and 
H3N2, to induce Het-I. Our study focused on the ability of a live attenuated vaccine 
expressing either H7N2 or H9N2 to protect against HPAI H5N1. Because it has been 
shown B cells have a role in Het-I and our vaccines contain that same internal genes 
from WF10att, we focused on the role of B cells in the ability of our WF10att live 
attenuated avian backbone to induce Het-I. We performed three different assays to 
examine the role of B cells in Het-I including serum passive transfer study, challenge 
study using B-cell knockout mice, and B cell ELISPOT.  
When naïve Balb/c mice were i.p. injected three times with serum collected 21 
dpv from mice immunized with the recombinant vaccines and challenged twenty-four 
hours after the final injection, only three mice receiving the ΔH5N1att serum 
survived challenge with HPAI H5N1, and one mouse survived challenge from each of 
the H7N2att or H9N2att sera receiving groups (Figure 17) suggesting a potential role 
for B cells in both homotypic and heterosubtypic challenge with our WF10att 
backbone. In addition, no JhD-/- B cell knockout mice vaccinated with either of the 
recombinant vaccines and challenged with HPAI H5N1 survived challenge (Figure 
18). This data is in contrast to a previous report that immunized JhD-/- with a live 
attenuated H3N2 vaccine.  These mice were protected from challenge with lethal dose 




vaccines and challenge viruses were used when comparing our study to the Powell, et 
al study.  Our previous results suggest different vaccines subtypes can induce a 
difference in Het-I, which may be the reason these reports are conflicting. 
Furthermore, we then performed a B cell ELISPOT using plates coated with βPL-
inactivated ΔH5N1 virus to confirm the level of cross-reactive antibodies induced by 
our H7N2att vaccine. Lung cells isolated from mice immunized with H7N2att or 
H9N2att had cross-reactive antibody-secreting cells targeted to the ΔH5N1 virus 
(Figure 19a). No ASCs were detected in the spleen for any of the vaccinated mice, 
suggesting that our WF10att backbone induces a local immune response in the lungs 
post vaccination and not a systemic antibody immune response (Figure 19b). More 
studies need to be performed to determine the specificity of these heterosubtypic 
antibodies and determine the role they may play in protecting H7N2att immunized 
mice from HPAI H5N1 challenge. However, together all these results further indicate 
a role for antibodies in Het-I.  
Similar results were observed with both the H7N2att and H9N2att vaccinated 
mice indicating a role for other immune mechanisms. The passive transfer study 
should be repeated using convalescent sera as a positive control and serum should be 
injected through the tail vein. Also the JhD-/- challenge study should be repeated 
using lower doses of challenge virus including 0.5, 1.0, 5, and 10 MLD50 of HPAI 
H5N1 in order to confirm the role of antibodies in Het-I. This will allow us to better 
understand the role of B cells in Het-I induced by our WF10att backbone. 
Although our results suggest a role for B cells in Het-I, other immune 




focused on the ability of live attenuated vaccines to induce Het-I. It is hypothesized 
that the internal influenza antigens, specifically the NP and M genes, play a major 
role in Het-I because internal genes are more conserved between different subtypes. It 
is also thought that CD8+ T cells play a major role in Het-I because they target 
conserved viral proteins, specifically the NP and M proteins (Townsend, Rothbard et 
al. 1986). Therefore, we focused on the role of T cells in Het-I. Previous research has 
examined the mechanism of Het-I and found an important role for both CD8+ and 
CD4+ T cells (Benton, Misplon et al. 2001; Droebner, Haasbach et al. 2008; Kreijtz, 
Bodewes et al. 2009; Perrone, Ahmad et al. 2009). In contrast, others have found that 
CTLs are not necessary for Het-I and found that antibodies are more important 
(Nguyen, van Ginkel et al. 2001; Droebner, Haasbach et al. 2008; Perrone, Ahmad et 
al. 2009).  
We were unable to find a difference in levels of proinflammatory cytokines 
IFN-γ, IL-1β, or TNF-α post vaccination with the recombinant vaccines (Figure 20), 
which was surprising. The H7N2att vaccine replicated in the lungs of Balb/c mice at 
3 dpv while both the ΔH5N1att and H9N2att vaccines were not detected. We thought 
the ability of this vaccine to replicate would induce an immune response including a 
difference in cytokine expression that may result in the protection from HPAI H5N1 
challenge. There potentially could be a difference in the level of cytokines in lung 
homogenates at different time points earlier post vaccination, either 1 dpv or 2 dpv. 
Also if we examine other compartments such as draining lymph nodes or 
bronchoalveolar lavage, we may find a difference in the cytokine levels that may 




To further determine the role of other immune cells in Het-I, we performed an 
IFN-γ ELISPOT using the lung and spleen cells isolated from Balb/c mice immunized 
with the recombinant vaccines. We observed IFN-γ secreting cells from all of the 
vaccine groups within the lung cells at both 14 and 21 dpv, (Figure 21) indicating a 
local immune response in the lungs was induced by all the recombinant vaccines. In 
contrast, spleen cells from both ΔH5N1att and H7N2att immunized mice secreted 
IFN-γ at 21 dpv (Figure 21) suggesting that both recombinant vaccines are able to 
induce a systemic immune response post vaccination. Also we detected higher levels 
of Granzyme B secreting cells in the spleen cells isolated from H7N2att immunized 
mice than the H9N2att mice when these cells were stimulated with ConA. Again 
suggesting the H7N2att recombinant vaccine is able to induce a systemic response 
post vaccination, which may play a role in the induction of Het-I. The Granzyme B 
data suggest that the H7N2 surface glycoproteins induce increased levels of CTLs 
post vaccination, which could be a result of the ability of this vaccine to replicate or 
there could be a difference in the cell types infected by the vaccines. Also the 
increased level of Granzyme B could result in the killing of infected cells by 
antibody-dependent cell mediated cytotoxicity (ADCC).  In ADCC, infected cells are 
eliminated when Fc receptor-bearing NK cells recognize antibody-coated infected 
cells and secret perforins and granzymes that kill the targeted cell (Jegerlehner, 
Schmitz et al. 2004). This may result in the induction of Het-I. 
Understanding the mechanisms in Het-I remains a top priority as influenza 
viruses continue to circulate and change. We are unable to predict when the next 




concerted effort to analyze the ability and mechanisms used by all subtypes of 
influenza viruses to induce Het-I. In addition, more studies are needed to determine 
the ability of live attenuated vaccine to induce Het-I. Over time, vaccines have 
become more prevalent and it remains unknown if they can protect against different 
subtypes. Therefore, our studies focusing on the ability of H7N2 and H9N2 avian live 
attenuated vaccines to induce Het-I are needed because they expand our 
understanding of the molecular mechanisms regulating Het-I. Our results suggest a 
role for both B and T cells in Het-I induced by our live attenuated avian influenza 
backbone WF10att.  More studies are needed to truly understand how our H7N2att 
vaccine protects mice against HPAI H5N1.  The information gained will impact the 





Chapter 5: Conclusions 
 
5.1 Conclusions from dissertation research 
5.1.1 Avian WF10att backbone as a master donor for live attenuated vaccines in 
mammals and the induction of heterosubtypic immunity 
 The primary goal of this project was to determine if our WF10att backbone 
would provide protection for mice and ferrets. Previously, we observed that the 
WF10att backbone was protective against low pathogenic avian influenza (LPAI) and 
highly pathogenic avian influenza (HPAI) in chickens using a LPAI H7N2 and HPAI 
H5N1 challenge. The question arose whether this backbone could be used as a master 
donor for live attenuated vaccines for epidemic and pandemic influenza.  Therefore, 
we needed to know if the backbone was protective in mammals. We decided to use 
both the mouse and ferret models to determine if this backbone could be used as a 
master donor stain. In addition, current influenza vaccines are unable to induce 
heterosubtypic immunity (Het-I); therefore, we sought to determine if our WF10att 
backbone could induce Het-I using vaccines expressing H7N2 or H9N2 surface 
glycoproteins.  
 First, we determined that the recombinant WF10att vaccines carrying the 
surface glycoproteins, H1N1, ΔH5N1, H7N2, or H9N2 are all attenuated in female 
Balb/c and C7BL/6 mice. We observed Balb/c mice vaccinated with H1N1att, 
H7N2att, or H9N2att and challenged with an H1N1 lethal virus all survived the 
challenge. Therefore, with an H1N1 challenge, the WF10att backbone protects 




case with a lethal HPAI H5N1 challenge. Both Balb/c and C57BL/6 mice vaccinated 
with ΔH5N1att were at least partially protected from homotypic challenge with HPAI 
H5N1. However, mice vaccinated with a single dose of H7N2att were protected from 
HPAI H5N1 while mice vaccinated with a single dose of H9N2att were not protected. 
H9N2att vaccinated mice needed two doses of vaccine to survive the HPAI H5N1 
challenge.  
Since we saw a difference in Het-I depending on the surface glycoprotein 
expressed on the WF10att vaccine backbone, we sought to determine if this 
difference in Het-I was species dependent. We used the ferret model because ferrets 
are considered the best model for human influenza. We vaccinated ferrets with the 
same recombinant WF10att vaccines expressing different surface glycoproteins, 
ΔH5N1, H7N2, or H9N2 and challenged them with HPAI H5N1. We found that 
ferrets vaccinated with ΔH5N1att were protected against lethal challenge with HPAI 
H5N1. However, in the ferret model there was a difference in Het-I when compared 
to the mouse model. H9N2att survived challenge against HPAI H5N1 (100% 
survival) while the H7N2att vaccinated ferrets (50% survival) were partially 
protected from challenge. The data from the mouse and ferret models confirm that the 
WF10att backbone can be used as a master donor strain, similar to the current live 
attenuated master donor strain A/Ann Arbor/6/60 H2N2, for epidemic and pandemic 
influenza vaccines. The backbone protected mice against homotypic challenge with 
both H1N1 and H5N1 viruses, and ferrets were protected against homotypic 
challenge with HPAI H5N1. Het-I was different depending on the surface 




results further highlighted the idea that the surface glycoproteins influence the 
induction of Het-I, which has been shown in the literature previously (Rutigliano, 
Morris et al. 2010). One new discovery was that the induction of Het-I is different 
depending on the species vaccinated. This information has not been reported in the 
literature previously. The question remains what mechanisms result in the induction 
of Het-I. 
5.1.2 Possible mechanisms of Het-I induced by WF10att vaccine backbone in 
mouse model 
 After observing a difference in Het-I in both the mouse and ferret models, we 
decided to determine the mechanisms of Het-I induced by our WF10att vaccine 
backbone using the mouse model due to the numerous reagents available to analyze 
the immune response. We first examined the role of cross-reactive antibodies in Het-
I.  Since the H7N2att vaccinated mice were protected from challenge with both H1N1 
and HPAI H5N1, it was possible the mice had cross-reactive neutralizing antibodies 
to the challenge virus. However, when we performed a microneutralization assay, we 
were unable to detect any cross-reactive neutralizing antibodies in the heterosubtypic-
vaccinated mice. In the absence of cross-reactive neutralizing antibodies, non-
neutralizing antibodies to the challenge virus may be involved in Het-I. Therefore, an 
ELISA was performed that was coated with the A/Vietnam/1203/2004 H5 protein. 
Similar to the microneutralization assay, no cross-reactive non-neutralizing antibodies 
to the H5 protein were detected in the H7N2att sera. However, the H9N2att sera had 
low levels of non-neutralizing antibodies targeted to the H5 protein when compared 




influenza HAs, which is based on primary sequence. When an ELISA coated with β-
propiolactone (βPL) inactivated ΔH5N1 virus, we detected similar levels of non-
neutralizing antibodies directed to non-HA viral proteins in both H7N2att and 
H9N2att sera. These results suggest a role for non-neutralizing antibodies directed to 
non-HA viral proteins in Het-I. 
 We sought to further determine the role of antibodies in Het-I, we performed a 
passive transfer study using sera from Balb/c mice vaccinated with recombinant 
vaccines and collected at 21 dpv. Three out of the ten naïve mice that received the 
ΔH5N1att sera by intraperitoneal (i.p.) injection survived challenge with HPAI H5N1 
while one out of ten of the naïve mice that received the H7N2att or H9N2att sera 
survived the challenge suggesting a small role for antibodies in both homotypic and 
heterosubtypic challenge. Also we vaccinated and challenged JhD-/- mice, mice that 
lack mature B-lymphocytes, and found that no mice survived challenge with HPAI 
H5N1 further indicating a role for antibodies in Het-I. The role of B cells in Het-I was 
confirmed using a B cell ELISPOT that was coated with βPL-inactivated ΔH5N1 
virus. Similar to the ELISA assay, we observed cross-reactive antibodies being 
secreted from the B cells isolated from the lungs of H7N2att vaccinated mice further 
suggesting a role for antibodies in Het-I with our WF10att backbone in Balb/c mice. 
 After determining a role for B cells in Het-I, there was a possibility that T 
cells are involved in Het-I induced by our WF10att backbone. We next examined the 
role of cytokines induced post vaccination. H7N2att was the only recombinant 
vaccine detected in the lungs of Balb/c mice 3 dpv. Therefore, it was possible that 




cytokine profile in the lung homogenates of vaccinated Balb/c mice at 3 and 5 dpv. 
We analyzed IFN-γ, IL-1β, and TNF-α and observed no difference between any of the 
three cytokines between each of the vaccine groups. These results suggest the 
cytokine profile is not involved in Het-I. We also performed IFN-γ and Granzyme B 
ELISPOTs on spleen and lung cells isolated from vaccinated mice and found that 
IFN-γ and Granzyme B spots were detected in the vaccinated mice suggesting a role 
for T cells or NK cells in Het-I. With regards to our WF10att backbone, our results 
suggest a role for both B and T cells in the induction of Het-I. Further studies are 
necessary to pin point the exact role of the different immune cells in Het-I. 
5.2 Future prospects 
5.2.1 Immune components involved in heterosubtypic immunity 
 The results in this thesis suggest a role for B cells in Het-I induced by our 
WF10att backbone, however further studies are needed to confirm their role. The 
serum passive transfer studies should be repeated using convalescent sera from HPAI 
H5N1 challenge as a positive control. Also the naïve mice should receive multiple 
injections of the sera through the tail vein, and varying doses of HPAI H5N1 
challenge virus  (0.5, 1, 5, 10, and 20 MLD50) should be used in order to observe 
subtle differences in the role antibodies in Het-I. In addition to passive transfer 
studies, the immunization and challenge studies in JhD-/- mice should be repeated 
using varying doses of HPAI H5N1 challenge virus (0.5, 1, 5, 10, and 20 MLD50) to 
tease out the role of antibodies in Het-I. These experiments may help confirm a role 




 We only performed IFN-γ and Granzyme B ELISPOTs, which suggest a role 
for T cells or NK cells in Het-I; however more needs to be done to confirm a role for 
other immune cells. Performing T cell passive transfer studies are needed to confirm a 
role for T cells—transfer at least 2.0 x 106 cells per mouse isolated from vaccinated 
mice into the tail vein of naïve Balb/c mice and challenge with varying doses of 
HPAI H5N1 (0.5, 1, 5, 10, and 20 MLD50). This type of study will provide a better 
understanding of the role of T cells in Het-I. Intracellular cytokine staining and IFN-γ 
ELISPOTs should be performed post challenge with the different vaccines to see if 
there is a difference in the cytokine profiles and IFN-γ secreting cells between the 
vaccines. This information may shed light on why the H7N2att vaccine is able to 
protect against HPAI H5N1 with a single dose and H9N2att is unable to protect 
against HPAI H5N1 in mice. In addition, performing experiments in ferrets is also 
important to determine why there is a difference in Het-I between the mouse and 
ferret models. 
5.2.2 Analysis of different surface glycoproteins expressed by WF10att backbone 
 Previous reports have observed a difference in protection depending on the 
priming subtype and the challenge virus subtype (Rutigliano, Morris et al. 2010). Our 
results further support this idea using avian influenza subtypes.  It remains unclear 
whether different influenza subtypes infect different cells types. Experiments need to 
be performed that determine the cell types infected with our WF10att backbone 
expressing the different surface glycoproteins, H1N1, ΔH5N1, H7N2, or H9N2. We 
developed a shuffled influenza virus that is able to express GFP; therefore, flow 




information could shed light on the ability of influenza viruses to transmit if there is a 
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